⚙

Pathophysiology

4

Leptomeningeal Melanocytic Tumor Formation

Meningeal melanocytoma arises from melanocytes in the leptomeninges and forms a circumscribed primary CNS melanocytic neoplasm. The tumor is usually benign or low-grade, but its anatomic location can produce mass effect and neurologic symptoms.

leptomeningeal melanocyte link

melanocytic tumor cell proliferation link ↑ INCREASED

leptomeninx link central nervous system link

Downstream

G-alpha-q Pathway Activation Adult circumscribed CNS melanocytic tumors often carry GNAQ or GNA11 driver alterations.

Neurologic Mass Effect Tumor growth in intracranial or spinal meningeal spaces can produce headaches, seizures, weakness, or other neurologic deficits.

Show evidence (2 references)

DOI:10.1093/jscr/rjae332 SUPPORT Human Clinical

"Primary intracranial melanocytoma is an uncommon benign pigmented tumor arising from leptomeningeal melanocytes."

This case report and review states the leptomeningeal melanocyte origin of the tumor.

DOI:10.1111/bpa.12241 SUPPORT Human Clinical

"Primary melanocytic tumors of the central nervous system (CNS) represent a spectrum of rare tumors."

The molecular review supports classifying meningeal melanocytoma within the rare primary CNS melanocytic tumor spectrum.

G-alpha-q Pathway Activation

Circumscribed primary meningeal melanocytic tumors, including many melanocytomas, commonly carry somatic alterations in GNAQ, GNA11, or related G-alpha-q pathway genes. These alterations distinguish them from many metastatic melanomas and support integrated molecular diagnosis.

GNAQ link GNA11 link PLCB4 link CYSLTR2 link

G protein-coupled receptor signaling pathway link ⚠ ABNORMAL MAPK cascade link ⚠ ABNORMAL Hippo-YAP signaling link ⚠ ABNORMAL

Downstream

Melanocytic Tumor Cell Proliferation G-alpha-q pathway activation contributes to melanocytic neoplasm growth.

Show evidence (3 references)

DOI:10.3390/cancers16142508 SUPPORT Human Clinical

"Molecular analysis can detect specific mutations, including GNAQ, GNA11, SF3B1, EIF1AX, BAP1, that are typically found in circumscribed primary meningeal melanocytic tumors and not in other melanocytic lesions, whereas NRAS and BRAF mutations are typical for diffuse primary meningeal melanocytic tumors."

The EURACAN review supports GNAQ/GNA11 and related molecular alterations as distinguishing circumscribed primary meningeal melanocytic tumors.

DOI:10.1111/bpa.12228 SUPPORT Human Clinical

"Melanocytomas carried GNAQ/11 mutations and presented with CNV involving chromosomes 3 and 6."

Human tumor methylome and genomic profiling supports GNAQ/GNA11 alterations in melanocytomas.

PMID:30773340 PARTIAL In Vitro

"Analysis of the FAK-regulated transcriptome demonstrated that GNAQ stimulates YAP through FAK."

Mechanistic GNAQ-driven melanoma models support Hippo-YAP signaling as a plausible downstream pathway for G-alpha-q-mutant melanocytic tumors, but this evidence is not meningeal melanocytoma-specific.

Melanocytic Tumor Cell Proliferation

Oncogenic G-alpha-q pathway alterations support proliferation of the circumscribed melanocytic tumor mass.

melanocyte link

melanocytic tumor cell proliferation link ↑ INCREASED

Downstream

Neurologic Mass Effect Tumor cell proliferation expands the meningeal mass and can compress adjacent brain, spinal cord, roots, or thecal sac structures.

Show evidence (1 reference)

DOI:10.1111/bpa.12241 SUPPORT Human Clinical

"Recently, novel insights in the molecular alterations underlying primary melanocytic tumors of the CNS were obtained, including different oncogenic mutations in tumors in adult patients (especially GNAQ, GNA11) vs. children (especially NRAS)."

The molecular review supports oncogenic GNAQ/GNA11 alterations in adult primary CNS melanocytic tumors.

Neurologic Mass Effect

Intracranial or spinal meningeal melanocytoma can compress adjacent CNS structures, producing headache, seizures, limb weakness or sensory symptoms, and sphincter dysfunction depending on tumor location.

central nervous system link spinal cord link

Show evidence (2 references)

DOI:10.1093/jscr/rjae332 SUPPORT Human Clinical

"We report a case of a 19-year-old woman presenting with progressively worsening headaches, nausea, emesis, and generalized weakness"

Intracranial case evidence supports mass-effect symptoms including headache and weakness.

PMID:33410365 SUPPORT Human Clinical

"Magnetic resonance imaging of the lumbar spine revealed a mass with thecal sac compression which was hypointense on T2-weighted images and hyperintense on T1-weighted images."

Spinal recurrence evidence supports local thecal sac compression as a mechanism for neurologic deficits.

✶

Histopathology

4

Primary Leptomeningeal Melanocytoma

Diagnosis is confirmed by histopathology with immunohistochemical support, particularly when imaging resembles a more common meningeal tumor such as meningioma.

Show evidence (1 reference)

DOI:10.3389/pore.2023.1611482 SUPPORT Human Clinical

"Histopathological examination, supported by immunohistochemistry, confirmed primary leptomeningeal melanocytoma."

The report directly supports histopathology and immunohistochemistry as diagnostic confirmation.

Melanocytic Immunohistochemical Marker Panel

A melanocytic immunohistochemical pattern, with HMB-45, S-100, and Melan-A positivity and epithelial/glial marker negativity, supports melanocytoma and helps distinguish it from meningioma, glioma, and metastatic mimics.

Show evidence (2 references)

DOI:10.4103/1793-5482.131068 SUPPORT Human Clinical

"Immunohistochemistry was performed, which showed positivity for HMB-45, S-100, Vimentin and Melan-A."

This spinal melanocytoma case directly documents positive melanocytic markers.

DOI:10.4103/1793-5482.131068 SUPPORT Human Clinical

"The cells were negative for cytokeratin, epithelial membrane antigen, Glial fibrillary acidic protein and neuron-specific enolase."

The same case documents negative epithelial and glial markers, supporting differential diagnosis from mimics.

MIB-1/Ki-67 Proliferation Index

Low MIB-1/Ki-67 labeling supports low-grade melanocytoma, whereas elevated proliferative index may support intermediate-grade behavior when other histologic malignant criteria are absent.

Show evidence (2 references)

DOI:10.4103/1793-5482.131068 SUPPORT Human Clinical

"Mib-1 labeling index was less than 1%."

Low Mib-1/Ki-67 proliferation index supports low-grade melanocytoma histopathology.

PMID:19449182 SUPPORT Human Clinical

"The lesion showed no histological criteria of malignancy but did exhibit an elevated (8%) MIB-1/Ki-67 cell proliferative index, which suggested an intermediate-grade melanocytoma."

This case supports MIB-1/Ki-67 as a grading-relevant proliferation marker for intermediate-grade melanocytoma.

Melanotic CNS Tumor Molecular Profile

Methylation and mutation profiles can help classify melanotic nervous system tumors and distinguish melanocytoma from melanoma and schwannian mimics.

Show evidence (1 reference)

DOI:10.1111/bpa.12228 SUPPORT Human Clinical

"The methylome fingerprints assigned tumors to entity-specific groups."

Human tumor profiling supports methylome-based classification of melanotic nervous system tumors.

⬡

Pathograph

Use the checkboxes to hide or show graph categories. Hover nodes for evidence and cross-linked metadata.

●

Phenotypes

11

Genitourinary 2

Urinary Retention Urinary retention (HP:0000016)

Show evidence (1 reference)

PMID:33410365 SUPPORT Human Clinical

"CASE REPORT: We report a case of a 33-year-old Asian male who developed progressive weakness and numbness of the bilateral lower extremities as well as urinary retention five years after complete tumour resection of lumbar spinal meningeal melanocytoma."

This recurrent lumbar spinal case directly documents urinary retention.

Neurogenic Bladder or Sphincter Dysfunction Neurogenic bladder (HP:0000011)

Show evidence (1 reference)

PMID:33410365 PARTIAL Human Clinical

"Clinicians should consider the possibility of these rare tumours at any level of the spine, and be aware of sphincter dysfunction in addition to motor and sensory deficits of extremities."

The recurrent spinal case explicitly warns about sphincter dysfunction; urinary retention in the same report supports the neurogenic bladder mapping.

Musculoskeletal 1

Generalized Weakness Muscle weakness (HP:0001324)

Show evidence (1 reference)

DOI:10.1093/jscr/rjae332 SUPPORT Human Clinical

"We report a case of a 19-year-old woman presenting with progressively worsening headaches, nausea, emesis, and generalized weakness"

The case report directly documents generalized weakness as part of the presentation.

Nervous System 4

Headache Headache (HP:0002315)

Show evidence (1 reference)

DOI:10.1093/jscr/rjae332 SUPPORT Human Clinical

"We report a case of a 19-year-old woman presenting with progressively worsening headaches, nausea, emesis, and generalized weakness"

The case report directly documents progressive headache among presenting symptoms.

Seizure Seizure (HP:0001250)

Show evidence (1 reference)

DOI:10.3389/pore.2023.1611482 SUPPORT Human Clinical

"Case Report: A 32-year-old female presented with syncope and seizures, leading to the discovery of two left-sided supratentorial lesions initially misidentified as convexity meningiomas."

The case report directly supports seizures as a presenting phenotype for supratentorial meningeal melanocytoma.

Lower Extremity Paresthesia and Numbness Paresthesia (HP:0003401)

Show evidence (1 reference)

PMID:1299241 SUPPORT Human Clinical

"This patient presented clinically with paraparesis, tingling sensation and numbness of both lower extremities of 4 months duration."

The spinal case report supports paresthesia and numbness as sensory manifestations.

Progressive Myelopathy Myelopathy (HP:0002196)

Show evidence (1 reference)

DOI:10.1093/jscr/rjad002 SUPPORT Human Clinical

"We present a case report of a 56-year-old man who presented to our unit with a 4-month history of lower limb weakness and a sensory level at T6."

Lower-limb weakness with a thoracic sensory level supports a spinal myelopathy presentation.

Constitutional 2

Radicular Pain Pain (HP:0012531)

Show evidence (1 reference)

PMID:21492734 SUPPORT Human Clinical

"This patient presented clinically with severe radiating pain on the right lower extremity."

The S1 root sheath case supports radicular or radiating pain as a spinal presentation.

Back Pain Back pain (HP:0003418)

Show evidence (1 reference)

PMID:29780233 SUPPORT Human Clinical

"A 5-year-old male presented with a 4-month history of non-radiating low back pain persistent at rest, with otherwise non-remarkable medical history."

This pediatric spinal case directly documents persistent low back pain.

Other 2

Paraparesis Paraparesis (HP:0002385)

Show evidence (1 reference)

PMID:1299241 SUPPORT Human Clinical

"This patient presented clinically with paraparesis, tingling sensation and numbness of both lower extremities of 4 months duration."

The spinal case report directly documents paraparesis in meningeal melanocytoma.

Tetraparesis Tetraparesis (HP:0002273)

Show evidence (1 reference)

DOI:10.4103/ajns.AJNS_327_20 SUPPORT Human Clinical

"We present the case of a 29 years old female who presented with a recurrent lesion in cervical spine and rapidly progressing quadriparesis."

Quadriparesis is synonymous with tetraparesis and is directly reported in a recurrent cervical spinal case.

🧬

Genetic Associations

1

GNAQ/GNA11 pathway alterations (Somatic driver alterations in circumscribed primary meningeal melanocytic tumors.)

Show evidence (2 references)

DOI:10.1111/bpa.12241 SUPPORT Human Clinical

"Recently, novel insights in the molecular alterations underlying primary melanocytic tumors of the CNS were obtained, including different oncogenic mutations in tumors in adult patients (especially GNAQ, GNA11) vs. children (especially NRAS)."

The review supports GNAQ/GNA11 as major adult primary CNS melanocytic tumor alterations.

DOI:10.1111/bpa.12228 SUPPORT Human Clinical

"Melanocytomas carried GNAQ/11 mutations and presented with CNV involving chromosomes 3 and 6."

Human tumor profiling supports GNAQ/GNA11 alterations and chromosome 3/6 copy-number variation in melanocytomas.

💊

Treatments

2

Gross Total Resection

Action: surgical procedure MAXO:0000004

Gross total surgical resection is the preferred local treatment for circumscribed meningeal melanocytoma when safely feasible and is associated with the best recurrence-free outcomes in retrospective data.

Mechanism Target:

INHIBITS Leptomeningeal Melanocytic Tumor Formation — Surgical resection removes the circumscribed melanocytic tumor mass.

Show evidence (2 references)

DOI:10.3390/cancers14235851 SUPPORT Human Clinical

"Surgery is the preferred therapeutic approach, and total resection is associated with the best outcome."

The retrospective meta-analysis supports surgery and total resection as preferred treatment.

DOI:10.1002/cncr.20296 SUPPORT Human Clinical

"CTR was found to be significantly superior to ITR with regard to both local control and survival."

The pooled therapy analysis supports complete resection over incomplete resection for local control and survival.

Adjuvant Radiotherapy

Action: radiation therapy MAXO:0000014

Radiotherapy is considered after incomplete resection, recurrence, or aggressive features; retrospective evidence suggests benefit after incomplete resection but no definitive prospective standard exists.

Mechanism Target:

INHIBITS Leptomeningeal Melanocytic Tumor Formation — Adjuvant radiation is used to improve local control when residual or recurrent tumor remains.

Show evidence (2 references)

DOI:10.3390/cancers14235851 SUPPORT Human Clinical

"Patients with partial resection or tumor recurrence benefit from adjuvant radiotherapy, whereas chemo- or immunotherapies do not improve the disease course."

The meta-analysis supports adjuvant radiotherapy in partial resection or recurrence settings and notes limited systemic therapy benefit.

DOI:10.1002/cncr.20296 SUPPORT Human Clinical

"Outcome was significantly improved by RT after ITR."

The older pooled therapy analysis supports radiotherapy after incomplete resection.

🔬

Clinical Trials

1

NCT05984108 NOT_APPLICABLE UNKNOWN

Observational registry study of clinical, radiological, histological, and molecular features of CNS melanocytic tumors, including melanocytoma and intermediate-grade melanocytoma.

Show evidence (1 reference)

clinicaltrials:NCT05984108 SUPPORT Human Clinical

"The WHO classification of tumors of the central nervous system in its most recent version (2021) distinguishes on the one hand the circumscribed melanocytic tumors including melanocytoma, benign, and its slope malignant, meningeal melanoma, with an intermediate grade lesion in between, called..."

The ClinicalTrials.gov cache supports relevance of the MelaMen registry to circumscribed CNS melanocytic tumors and melanocytoma classification.

{ }

Source YAML

click to show

name: Meningeal Melanocytoma
creation_date: "2026-05-11T17:51:03Z"
updated_date: "2026-05-11T20:18:00Z"
description: >-
  Meningeal melanocytoma is a rare, usually well-differentiated melanocytic
  neoplasm arising from leptomeningeal melanocytes. It most often behaves as a
  low-grade central nervous system tumor, but local recurrence and malignant
  progression can occur.
categories:
- Central Nervous System Tumor
- Meningeal Tumor
- Melanocytic Neoplasm
parents:
- central nervous system melanocytic neoplasm
- meningeal neoplasm
disease_term:
  preferred_term: meningeal melanocytoma
  term:
    id: MONDO:0016746
    label: meningeal melanocytoma
prevalence:
- population: General population
  percentage: 1:10,000,000 incidence
  notes: Published retrospective literature synthesis describes meningeal melanocytoma as ultra-rare.
  evidence:
  - reference: DOI:10.3390/cancers14235851
    reference_title: "How Should We Treat Meningeal Melanocytoma? A Retrospective Analysis of Potential Treatment Strategies"
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "Background: Meningeal melanocytomas (MM) are rare primary melanocytic tumors of the leptomeninges with an incidence of 1:10,000,000."
    explanation: This retrospective meta-analysis provides the incidence estimate used for the prevalence summary.
progression:
- phase: Local recurrence and malignant transformation
  notes: >-
    Most lesions are histologically benign, but incomplete resection, recurrence,
    leptomeningeal spread, and malignant transformation are reported.
  evidence:
  - reference: DOI:10.3390/cancers14235851
    reference_title: "How Should We Treat Meningeal Melanocytoma? A Retrospective Analysis of Potential Treatment Strategies"
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "Malignant transformation was described in 18 patients."
    explanation: The meta-analysis documents malignant transformation among published meningeal melanocytoma cases.
  - reference: DOI:10.1155/2021/7306432
    reference_title: "Suprasellar Melanocytoma with Leptomeningeal Seeding: An Aggressive Clinical Course for a Histologically Benign Tumor"
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "Conclusion. Thus, primary sellar melanocytomas with leptomeningeal spread are an extremely rare phenomenon."
    explanation: This human case report directly supports leptomeningeal dissemination as a rare progression pattern.
pathophysiology:
- name: Leptomeningeal Melanocytic Tumor Formation
  description: >-
    Meningeal melanocytoma arises from melanocytes in the leptomeninges and
    forms a circumscribed primary CNS melanocytic neoplasm. The tumor is usually
    benign or low-grade, but its anatomic location can produce mass effect and
    neurologic symptoms.
  cell_types:
  - preferred_term: leptomeningeal melanocyte
    term:
      id: CL:0000148
      label: melanocyte
  locations:
  - preferred_term: leptomeninx
    term:
      id: UBERON:0000391
      label: leptomeninx
  - preferred_term: central nervous system
    term:
      id: UBERON:0001017
      label: central nervous system
  biological_processes:
  - preferred_term: melanocytic tumor cell proliferation
    modifier: INCREASED
    term:
      id: GO:0008283
      label: cell population proliferation
  evidence:
  - reference: DOI:10.1093/jscr/rjae332
    reference_title: "Intracranial meningeal melanocytoma: a case report and literature review"
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "Primary intracranial melanocytoma is an uncommon benign pigmented tumor arising from leptomeningeal melanocytes."
    explanation: This case report and review states the leptomeningeal melanocyte origin of the tumor.
  - reference: DOI:10.1111/bpa.12241
    reference_title: "Primary Melanocytic Tumors of the Central Nervous System: a Review with Focus on Molecular Aspects"
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "Primary melanocytic tumors of the central nervous system (CNS) represent a spectrum of rare tumors."
    explanation: The molecular review supports classifying meningeal melanocytoma within the rare primary CNS melanocytic tumor spectrum.
  downstream:
  - target: G-alpha-q Pathway Activation
    causal_link_type: INDIRECT_KNOWN_INTERMEDIATES
    description: Adult circumscribed CNS melanocytic tumors often carry GNAQ or GNA11 driver alterations.
  - target: Neurologic Mass Effect
    causal_link_type: DIRECT
    description: Tumor growth in intracranial or spinal meningeal spaces can produce headaches, seizures, weakness, or other neurologic deficits.
- name: G-alpha-q Pathway Activation
  description: >-
    Circumscribed primary meningeal melanocytic tumors, including many
    melanocytomas, commonly carry somatic alterations in GNAQ, GNA11, or related
    G-alpha-q pathway genes. These alterations distinguish them from many
    metastatic melanomas and support integrated molecular diagnosis.
  genes:
  - preferred_term: GNAQ
    term:
      id: hgnc:4390
      label: GNAQ
  - preferred_term: GNA11
    term:
      id: hgnc:4379
      label: GNA11
  - preferred_term: PLCB4
    term:
      id: hgnc:9059
      label: PLCB4
  - preferred_term: CYSLTR2
    term:
      id: hgnc:18274
      label: CYSLTR2
  biological_processes:
  - preferred_term: G protein-coupled receptor signaling pathway
    modifier: ABNORMAL
    term:
      id: GO:0007186
      label: G protein-coupled receptor signaling pathway
  - preferred_term: MAPK cascade
    modifier: ABNORMAL
    term:
      id: GO:0000165
      label: MAPK cascade
  - preferred_term: Hippo-YAP signaling
    modifier: ABNORMAL
    term:
      id: GO:0035329
      label: hippo signaling
  evidence:
  - reference: DOI:10.3390/cancers16142508
    reference_title: "Primary Meningeal Melanocytic Tumors of the Central Nervous System: A Review from the Ultra-Rare Brain Tumors Task Force of the European Network for Rare Cancers (EURACAN)"
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "Molecular analysis can detect specific mutations, including GNAQ, GNA11, SF3B1, EIF1AX, BAP1, that are typically found in circumscribed primary meningeal melanocytic tumors and not in other melanocytic lesions, whereas NRAS and BRAF mutations are typical for diffuse primary meningeal melanocytic tumors."
    explanation: The EURACAN review supports GNAQ/GNA11 and related molecular alterations as distinguishing circumscribed primary meningeal melanocytic tumors.
  - reference: DOI:10.1111/bpa.12228
    reference_title: "Melanotic Tumors of the Nervous System are Characterized by Distinct Mutational, Chromosomal and Epigenomic Profiles"
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "Melanocytomas carried GNAQ/11 mutations and presented with CNV involving chromosomes 3 and 6."
    explanation: Human tumor methylome and genomic profiling supports GNAQ/GNA11 alterations in melanocytomas.
  - reference: PMID:30773340
    reference_title: "A Platform of Synthetic Lethal Gene Interaction Networks Reveals that the GNAQ Uveal Melanoma Oncogene Controls the Hippo Pathway through FAK."
    supports: PARTIAL
    evidence_source: IN_VITRO
    snippet: "Analysis of the FAK-regulated transcriptome demonstrated that GNAQ stimulates YAP through FAK."
    explanation: Mechanistic GNAQ-driven melanoma models support Hippo-YAP signaling as a plausible downstream pathway for G-alpha-q-mutant melanocytic tumors, but this evidence is not meningeal melanocytoma-specific.
  downstream:
  - target: Melanocytic Tumor Cell Proliferation
    causal_link_type: DIRECT
    description: G-alpha-q pathway activation contributes to melanocytic neoplasm growth.
- name: Melanocytic Tumor Cell Proliferation
  description: >-
    Oncogenic G-alpha-q pathway alterations support proliferation of the
    circumscribed melanocytic tumor mass.
  cell_types:
  - preferred_term: melanocyte
    term:
      id: CL:0000148
      label: melanocyte
  biological_processes:
  - preferred_term: melanocytic tumor cell proliferation
    modifier: INCREASED
    term:
      id: GO:0008283
      label: cell population proliferation
  evidence:
  - reference: DOI:10.1111/bpa.12241
    reference_title: "Primary Melanocytic Tumors of the Central Nervous System: a Review with Focus on Molecular Aspects"
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "Recently, novel insights in the molecular alterations underlying primary melanocytic tumors of the CNS were obtained, including different oncogenic mutations in tumors in adult patients (especially GNAQ, GNA11) vs. children (especially NRAS)."
    explanation: The molecular review supports oncogenic GNAQ/GNA11 alterations in adult primary CNS melanocytic tumors.
  downstream:
  - target: Neurologic Mass Effect
    causal_link_type: DIRECT
    description: Tumor cell proliferation expands the meningeal mass and can compress adjacent brain, spinal cord, roots, or thecal sac structures.
- name: Neurologic Mass Effect
  description: >-
    Intracranial or spinal meningeal melanocytoma can compress adjacent CNS
    structures, producing headache, seizures, limb weakness or sensory symptoms,
    and sphincter dysfunction depending on tumor location.
  locations:
  - preferred_term: central nervous system
    term:
      id: UBERON:0001017
      label: central nervous system
  - preferred_term: spinal cord
    term:
      id: UBERON:0002240
      label: spinal cord
  evidence:
  - reference: DOI:10.1093/jscr/rjae332
    reference_title: "Intracranial meningeal melanocytoma: a case report and literature review"
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "We report a case of a 19-year-old woman presenting with progressively worsening headaches, nausea, emesis, and generalized weakness"
    explanation: Intracranial case evidence supports mass-effect symptoms including headache and weakness.
  - reference: PMID:33410365
    reference_title: "Recurrent spinal meningeal melanocytoma at lumbar spine level: a case report."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "Magnetic resonance imaging of the lumbar spine revealed a mass with thecal sac compression which was hypointense on T2-weighted images and hyperintense on T1-weighted images."
    explanation: Spinal recurrence evidence supports local thecal sac compression as a mechanism for neurologic deficits.
phenotypes:
- category: Neurologic
  name: Headache
  description: >-
    Intracranial meningeal melanocytoma can present with progressive headache
    as part of a mass-effect symptom complex.
  phenotype_term:
    preferred_term: Headache
    term:
      id: HP:0002315
      label: Headache
  evidence:
  - reference: DOI:10.1093/jscr/rjae332
    reference_title: "Intracranial meningeal melanocytoma: a case report and literature review"
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "We report a case of a 19-year-old woman presenting with progressively worsening headaches, nausea, emesis, and generalized weakness"
    explanation: The case report directly documents progressive headache among presenting symptoms.
- category: Neurologic
  name: Seizure
  description: >-
    Supratentorial meningeal melanocytoma may mimic meningioma and can present
    with seizure activity when cortical or adjacent supratentorial structures
    are involved.
  phenotype_term:
    preferred_term: Seizure
    term:
      id: HP:0001250
      label: Seizure
  evidence:
  - reference: DOI:10.3389/pore.2023.1611482
    reference_title: "Supratentorial meningeal melanocytoma mimicking meningioma: case report and literature review"
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "Case Report: A 32-year-old female presented with syncope and seizures, leading to the discovery of two left-sided supratentorial lesions initially misidentified as convexity meningiomas."
    explanation: The case report directly supports seizures as a presenting phenotype for supratentorial meningeal melanocytoma.
- category: Neurologic
  name: Generalized Weakness
  description: >-
    Weakness may occur in patients with intracranial lesions, reflecting mass
    effect or involvement of nearby CNS structures rather than a systemic muscle
    disease.
  phenotype_term:
    preferred_term: Generalized weakness
    term:
      id: HP:0001324
      label: Muscle weakness
  evidence:
  - reference: DOI:10.1093/jscr/rjae332
    reference_title: "Intracranial meningeal melanocytoma: a case report and literature review"
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "We report a case of a 19-year-old woman presenting with progressively worsening headaches, nausea, emesis, and generalized weakness"
    explanation: The case report directly documents generalized weakness as part of the presentation.
- category: Neurologic
  name: Paraparesis
  description: >-
    Spinal meningeal melanocytoma can present with lower-extremity weakness or
    partial paralysis when the spinal meninges and cord region are involved.
  phenotype_term:
    preferred_term: Paraparesis
    term:
      id: HP:0002385
      label: Paraparesis
  evidence:
  - reference: PMID:1299241
    reference_title: Spinal meningeal melanocytoma.
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "This patient presented clinically with paraparesis, tingling sensation and numbness of both lower extremities of 4 months duration."
    explanation: The spinal case report directly documents paraparesis in meningeal melanocytoma.
- category: Neurologic
  name: Tetraparesis
  description: >-
    Cervical spinal meningeal melanocytoma can present with rapidly progressive
    four-limb weakness when it causes severe cord compression.
  phenotype_term:
    preferred_term: Tetraparesis
    term:
      id: HP:0002273
      label: Tetraparesis
  evidence:
  - reference: DOI:10.4103/ajns.AJNS_327_20
    reference_title: "Recurrent meningeal melanocytoma of cervical spine: A rare case"
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "We present the case of a 29 years old female who presented with a recurrent lesion in cervical spine and rapidly progressing quadriparesis."
    explanation: Quadriparesis is synonymous with tetraparesis and is directly reported in a recurrent cervical spinal case.
- category: Neurologic
  name: Lower Extremity Paresthesia and Numbness
  description: >-
    Sensory symptoms in the lower extremities can accompany spinal meningeal
    melanocytoma.
  phenotype_term:
    preferred_term: Lower extremity paresthesia
    term:
      id: HP:0003401
      label: Paresthesia
  evidence:
  - reference: PMID:1299241
    reference_title: Spinal meningeal melanocytoma.
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "This patient presented clinically with paraparesis, tingling sensation and numbness of both lower extremities of 4 months duration."
    explanation: The spinal case report supports paresthesia and numbness as sensory manifestations.
- category: Neurologic
  name: Radicular Pain
  description: >-
    Spinal melanocytoma arising near nerve roots can mimic schwannoma and present
    with radiating lower-extremity pain.
  phenotype_term:
    preferred_term: Radicular pain
    term:
      id: HP:0012531
      label: Pain
  evidence:
  - reference: PMID:21492734
    reference_title: Spinal meningeal melanocytoma in the S-1 nerve root sheath with paraspinal extension mimicking schwannoma.
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "This patient presented clinically with severe radiating pain on the right lower extremity."
    explanation: The S1 root sheath case supports radicular or radiating pain as a spinal presentation.
- category: Neurologic
  name: Back Pain
  description: >-
    Spinal meningeal melanocytoma may present as persistent low back pain before
    focal neurologic deficits are evident.
  phenotype_term:
    preferred_term: Back pain
    term:
      id: HP:0003418
      label: Back pain
  evidence:
  - reference: PMID:29780233
    reference_title: "Spinal meningeal melanocytoma in a 5-year-old child: a case report and review of literature."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "A 5-year-old male presented with a 4-month history of non-radiating low back pain persistent at rest, with otherwise non-remarkable medical history."
    explanation: This pediatric spinal case directly documents persistent low back pain.
- category: Neurologic
  name: Progressive Myelopathy
  description: >-
    Thoracic or lumbar spinal meningeal melanocytoma can cause progressive
    myelopathic weakness and sensory-level findings through cord or thecal sac
    compression.
  phenotype_term:
    preferred_term: Progressive myelopathy
    term:
      id: HP:0002196
      label: Myelopathy
  evidence:
  - reference: DOI:10.1093/jscr/rjad002
    reference_title: "Intradural extramedullary meningeal melanocytoma: a case report and literature review"
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "We present a case report of a 56-year-old man who presented to our unit with a 4-month history of lower limb weakness and a sensory level at T6."
    explanation: Lower-limb weakness with a thoracic sensory level supports a spinal myelopathy presentation.
- category: Genitourinary
  name: Urinary Retention
  description: >-
    Lumbar or spinal recurrent meningeal melanocytoma can produce sphincter
    dysfunction with urinary retention.
  phenotype_term:
    preferred_term: Urinary retention
    term:
      id: HP:0000016
      label: Urinary retention
  evidence:
  - reference: PMID:33410365
    reference_title: "Recurrent spinal meningeal melanocytoma at lumbar spine level: a case report."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "CASE REPORT: We report a case of a 33-year-old Asian male who developed progressive weakness and numbness of the bilateral lower extremities as well as urinary retention five years after complete tumour resection of lumbar spinal meningeal melanocytoma."
    explanation: This recurrent lumbar spinal case directly documents urinary retention.
- category: Genitourinary
  name: Neurogenic Bladder or Sphincter Dysfunction
  description: >-
    Spinal meningeal melanocytoma can involve sphincter dysfunction and ongoing
    catheterization needs after spinal recurrence.
  phenotype_term:
    preferred_term: Neurogenic bladder or sphincter dysfunction
    term:
      id: HP:0000011
      label: Neurogenic bladder
  evidence:
  - reference: PMID:33410365
    reference_title: "Recurrent spinal meningeal melanocytoma at lumbar spine level: a case report."
    supports: PARTIAL
    evidence_source: HUMAN_CLINICAL
    snippet: "Clinicians should consider the possibility of these rare tumours at any level of the spine, and be aware of sphincter dysfunction in addition to motor and sensory deficits of extremities."
    explanation: The recurrent spinal case explicitly warns about sphincter dysfunction; urinary retention in the same report supports the neurogenic bladder mapping.
histopathology:
- name: Primary Leptomeningeal Melanocytoma
  diagnostic: true
  description: >-
    Diagnosis is confirmed by histopathology with immunohistochemical support,
    particularly when imaging resembles a more common meningeal tumor such as
    meningioma.
  evidence:
  - reference: DOI:10.3389/pore.2023.1611482
    reference_title: "Supratentorial meningeal melanocytoma mimicking meningioma: case report and literature review"
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "Histopathological examination, supported by immunohistochemistry, confirmed primary leptomeningeal melanocytoma."
    explanation: The report directly supports histopathology and immunohistochemistry as diagnostic confirmation.
- name: Melanocytic Immunohistochemical Marker Panel
  diagnostic: true
  description: >-
    A melanocytic immunohistochemical pattern, with HMB-45, S-100, and Melan-A
    positivity and epithelial/glial marker negativity, supports melanocytoma
    and helps distinguish it from meningioma, glioma, and metastatic mimics.
  evidence:
  - reference: DOI:10.4103/1793-5482.131068
    reference_title: "Intramedullary melanocytoma of thoracic spine: A rare case report"
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "Immunohistochemistry was performed, which showed positivity for HMB-45, S-100, Vimentin and Melan-A."
    explanation: This spinal melanocytoma case directly documents positive melanocytic markers.
  - reference: DOI:10.4103/1793-5482.131068
    reference_title: "Intramedullary melanocytoma of thoracic spine: A rare case report"
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "The cells were negative for cytokeratin, epithelial membrane antigen, Glial fibrillary acidic protein and neuron-specific enolase."
    explanation: The same case documents negative epithelial and glial markers, supporting differential diagnosis from mimics.
- name: MIB-1/Ki-67 Proliferation Index
  diagnostic: true
  description: >-
    Low MIB-1/Ki-67 labeling supports low-grade melanocytoma, whereas elevated
    proliferative index may support intermediate-grade behavior when other
    histologic malignant criteria are absent.
  evidence:
  - reference: DOI:10.4103/1793-5482.131068
    reference_title: "Intramedullary melanocytoma of thoracic spine: A rare case report"
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "Mib-1 labeling index was less than 1%."
    explanation: Low Mib-1/Ki-67 proliferation index supports low-grade melanocytoma histopathology.
  - reference: PMID:19449182
    reference_title: "Intracranial intermediate-grade meningeal melanocytoma with increased cellular proliferative index: an illustrative case associated with a nevus of Ota."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "The lesion showed no histological criteria of malignancy but did exhibit an elevated (8%) MIB-1/Ki-67 cell proliferative index, which suggested an intermediate-grade melanocytoma."
    explanation: This case supports MIB-1/Ki-67 as a grading-relevant proliferation marker for intermediate-grade melanocytoma.
- name: Melanotic CNS Tumor Molecular Profile
  diagnostic: true
  description: >-
    Methylation and mutation profiles can help classify melanotic nervous system
    tumors and distinguish melanocytoma from melanoma and schwannian mimics.
  evidence:
  - reference: DOI:10.1111/bpa.12228
    reference_title: "Melanotic Tumors of the Nervous System are Characterized by Distinct Mutational, Chromosomal and Epigenomic Profiles"
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "The methylome fingerprints assigned tumors to entity-specific groups."
    explanation: Human tumor profiling supports methylome-based classification of melanotic nervous system tumors.
genetic:
- name: GNAQ/GNA11 pathway alterations
  gene_term:
    preferred_term: GNAQ
    term:
      id: hgnc:4390
      label: GNAQ
  association: Somatic driver alterations in circumscribed primary meningeal melanocytic tumors.
  relationship_type: SOMATIC_DRIVER
  variant_origin: SOMATIC
  evidence:
  - reference: DOI:10.1111/bpa.12241
    reference_title: "Primary Melanocytic Tumors of the Central Nervous System: a Review with Focus on Molecular Aspects"
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "Recently, novel insights in the molecular alterations underlying primary melanocytic tumors of the CNS were obtained, including different oncogenic mutations in tumors in adult patients (especially GNAQ, GNA11) vs. children (especially NRAS)."
    explanation: The review supports GNAQ/GNA11 as major adult primary CNS melanocytic tumor alterations.
  - reference: DOI:10.1111/bpa.12228
    reference_title: "Melanotic Tumors of the Nervous System are Characterized by Distinct Mutational, Chromosomal and Epigenomic Profiles"
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "Melanocytomas carried GNAQ/11 mutations and presented with CNV involving chromosomes 3 and 6."
    explanation: Human tumor profiling supports GNAQ/GNA11 alterations and chromosome 3/6 copy-number variation in melanocytomas.
  notes: GNA11 is represented in the pathophysiology gene list; this genetic entry summarizes the shared GNAQ/GNA11 pathway axis and reported chromosome 3/6 copy-number changes.
diagnosis:
- name: Brain and spine MRI
  description: >-
    MRI helps recognize melanocytic lesions because melanin commonly produces
    T1 hyperintensity; imaging should be interpreted with clinical and pathology
    data because CNS melanocytic lesions overlap.
  diagnosis_term:
    preferred_term: magnetic resonance imaging procedure
    term:
      id: MAXO:0000424
      label: magnetic resonance imaging procedure
  results: MRI may show T1-hyperintense CNS melanocytic lesions and can reveal multifocal or leptomeningeal spread.
  evidence:
  - reference: DOI:10.1590/0004-282X-ANP-2021-0082
    reference_title: "Melanocytic lesions of the central nervous system: a case series"
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "On MRI, they are usually distinguished by a high signal on T1WI sequences, given the paramagnetic effect of melanin, thus making it difficult to differentiate among them."
    explanation: This CNS melanocytic lesion series supports MRI signal characteristics and diagnostic overlap.
  - reference: DOI:10.1093/jscr/rjae332
    reference_title: "Intracranial meningeal melanocytoma: a case report and literature review"
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "This case highlights the utility of specific imaging criteria such as diffusely increased T1 signal without enhancement in the initial diagnostic evaluation of intracranial melanocytoma."
    explanation: The case report supports MRI criteria as part of initial diagnostic evaluation.
- name: Histopathology with immunohistochemistry
  description: >-
    Tissue diagnosis with immunohistochemistry confirms meningeal melanocytoma
    and helps separate it from meningioma, metastatic melanoma, and other
    pigmented CNS lesions.
  diagnosis_term:
    preferred_term: diagnostic biopsy and immunohistochemistry
  results: Histopathology and immunohistochemistry establish primary leptomeningeal melanocytoma when imaging is ambiguous.
  evidence:
  - reference: DOI:10.3389/pore.2023.1611482
    reference_title: "Supratentorial meningeal melanocytoma mimicking meningioma: case report and literature review"
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "Histopathological examination, supported by immunohistochemistry, confirmed primary leptomeningeal melanocytoma."
    explanation: This case report directly supports histopathology with immunohistochemistry for diagnosis.
- name: Molecular profiling and methylation classification
  description: >-
    Sequencing for GNAQ/GNA11 and related alterations, plus methylation
    profiling where available, supports integrated diagnosis and helps identify
    aggressive or melanoma-spectrum tumors.
  diagnosis_term:
    preferred_term: genetic testing
    term:
      id: MAXO:0000127
      label: genetic testing
  results: Molecular analysis can detect alterations characteristic of circumscribed primary meningeal melanocytic tumors.
  evidence:
  - reference: DOI:10.3390/cancers16142508
    reference_title: "Primary Meningeal Melanocytic Tumors of the Central Nervous System: A Review from the Ultra-Rare Brain Tumors Task Force of the European Network for Rare Cancers (EURACAN)"
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "Molecular analysis can detect specific mutations, including GNAQ, GNA11, SF3B1, EIF1AX, BAP1, that are typically found in circumscribed primary meningeal melanocytic tumors and not in other melanocytic lesions, whereas NRAS and BRAF mutations are typical for diffuse primary meningeal melanocytic tumors."
    explanation: The EURACAN review supports molecular testing as useful for integrated diagnosis.
treatments:
- name: Gross Total Resection
  description: >-
    Gross total surgical resection is the preferred local treatment for
    circumscribed meningeal melanocytoma when safely feasible and is associated
    with the best recurrence-free outcomes in retrospective data.
  treatment_term:
    preferred_term: surgical procedure
    term:
      id: MAXO:0000004
      label: surgical procedure
  target_mechanisms:
  - target: Leptomeningeal Melanocytic Tumor Formation
    treatment_effect: INHIBITS
    description: Surgical resection removes the circumscribed melanocytic tumor mass.
  evidence:
  - reference: DOI:10.3390/cancers14235851
    reference_title: "How Should We Treat Meningeal Melanocytoma? A Retrospective Analysis of Potential Treatment Strategies"
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "Surgery is the preferred therapeutic approach, and total resection is associated with the best outcome."
    explanation: The retrospective meta-analysis supports surgery and total resection as preferred treatment.
  - reference: DOI:10.1002/cncr.20296
    reference_title: "Therapy of meningeal melanocytomas"
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "CTR was found to be significantly superior to ITR with regard to both local control and survival."
    explanation: The pooled therapy analysis supports complete resection over incomplete resection for local control and survival.
- name: Adjuvant Radiotherapy
  description: >-
    Radiotherapy is considered after incomplete resection, recurrence, or
    aggressive features; retrospective evidence suggests benefit after
    incomplete resection but no definitive prospective standard exists.
  treatment_term:
    preferred_term: radiation therapy
    term:
      id: MAXO:0000014
      label: radiation therapy
  target_mechanisms:
  - target: Leptomeningeal Melanocytic Tumor Formation
    treatment_effect: INHIBITS
    description: Adjuvant radiation is used to improve local control when residual or recurrent tumor remains.
  evidence:
  - reference: DOI:10.3390/cancers14235851
    reference_title: "How Should We Treat Meningeal Melanocytoma? A Retrospective Analysis of Potential Treatment Strategies"
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "Patients with partial resection or tumor recurrence benefit from adjuvant radiotherapy, whereas chemo- or immunotherapies do not improve the disease course."
    explanation: The meta-analysis supports adjuvant radiotherapy in partial resection or recurrence settings and notes limited systemic therapy benefit.
  - reference: DOI:10.1002/cncr.20296
    reference_title: "Therapy of meningeal melanocytomas"
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "Outcome was significantly improved by RT after ITR."
    explanation: The older pooled therapy analysis supports radiotherapy after incomplete resection.
clinical_trials:
- name: NCT05984108
  phase: NOT_APPLICABLE
  status: UNKNOWN
  description: >-
    Observational registry study of clinical, radiological, histological, and
    molecular features of CNS melanocytic tumors, including melanocytoma and
    intermediate-grade melanocytoma.
  evidence:
  - reference: clinicaltrials:NCT05984108
    reference_title: "Clinical, Radiological, Histological and Molecular Features of a Cohort of Melanocytic Tumors of the Central Nervous System"
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "The WHO classification of tumors of the central nervous system in its most recent version (2021) distinguishes on the one hand the circumscribed melanocytic tumors including melanocytoma, benign, and its slope malignant, meningeal melanoma, with an intermediate grade lesion in between, called intermediate grade melanocytoma."
    explanation: The ClinicalTrials.gov cache supports relevance of the MelaMen registry to circumscribed CNS melanocytic tumors and melanocytoma classification.

📚

References & Deep Research

Deep Research

1

Falcon ▸

Disease Characteristics Research Template

Edison Scientific Literature 31 citations 2026-05-11T14:24:07.986359

Question: You are an expert researcher providing comprehensive, well-cited information.

Provide detailed information focusing on: 1. Key concepts and definitions with current understanding 2. Recent developments and latest research (prioritize 2023-2024 sources) 3. Current applications and real-world implementations 4. Expert opinions and analysis from authoritative sources 5. Relevant statistics and data from recent studies

Format as a comprehensive research report with proper citations. Include URLs and publication dates where available. Always prioritize recent, authoritative sources and provide specific citations for all major claims.

Disease Characteristics Research Template

Target Disease

Disease Name: Meningeal Melanocytoma
MONDO ID: (if available)
Category:

Research Objectives

Please provide a comprehensive research report on Meningeal Melanocytoma covering all of the disease characteristics listed below. This report will be used to populate a disease knowledge base entry. Be thorough and cite primary literature (PMID preferred) for all claims.

For each section, suggested databases/resources are listed. These are the first places you should search for information on each topic.

1. Disease Information

Search first: OMIM, Orphanet, ICD-10/ICD-11, MeSH, PubMed

What is the disease? Provide a concise overview.
What are the key identifiers? (OMIM, Orphanet, ICD-10/ICD-11, MeSH, Mondo)
What are the common synonyms and alternative names?
Is the information derived from individual patients (e.g., EHR) or aggregated disease-level resources?

2. Etiology

Disease Causal Factors: What are the primary causes? (genetic, environmental, infectious, mechanistic)
Risk Factors:

Search first: PubMed, Cochrane Library, UpToDate, clinical guidelines, ClinVar, ClinGen, GWAS Catalog, PheGenI, CTD, CDC, WHO, epidemiological databases
Genetic risk factors (causal variants, susceptibility loci, modifier genes)
Environmental risk factors (toxins, lifestyle, occupational exposures, age, sex, family history)
Protective Factors:

Search first: PubMed, Cochrane Library, clinical trial databases, GWAS Catalog, gnomAD, WHO, CDC, nutrition databases
Genetic protective factors (protective variants, modifier alleles)
Environmental protective factors (diet, lifestyle, exposures that reduce risk)
Gene-Environment Interactions: How do genetic and environmental factors interact to influence disease?

Search first: CTD, PubMed, PheGenI, GxE databases

3. Phenotypes

Search first: HPO (Human Phenotype Ontology), OMIM, Orphanet, PubMed, clinicaltrials.gov, MedDRA, SNOMED CT, DECIPHER, LOINC

For each phenotype, provide: - Phenotype type: symptoms, clinical signs, physical manifestations, behavioral changes, or laboratory abnormalities

For symptoms/signs: HPO, OMIM, Orphanet, PubMed For behavioral changes: HPO, DSM, RDoC (Research Domain Criteria), PubMed For laboratory abnormalities: LOINC, SNOMED CT, LabTests Online, PubMed - Phenotype characteristics: Search first: OMIM, Orphanet, HPO, PubMed - Age of symptom onset (neonatal, childhood, adult-onset, late-onset) - Symptom severity (mild, moderate, severe, variable) - Symptom progression (stable, progressive, episodic, fluctuating) - Frequency among affected individuals (percentage or qualitative) - Quality of life impact: Effects on daily functioning and well-being (per-phenotype when possible) Search first: EQ-5D database, SF-36, WHO QOL databases, PubMed - Suggest HPO (Human Phenotype Ontology) terms for each phenotype

4. Genetic/Molecular Information

Causal Genes: Gene mutations or chromosomal abnormalities responsible for disease (gene symbols, OMIM IDs)

Search first: OMIM, ClinVar, HGMD, Ensembl, NCBI Gene
Pathogenic Variants:
Affected genes (gene symbols, HGNC IDs) > Search first: OMIM, NCBI Gene, Ensembl, HGNC, UniProt, GeneCards
Variant classification (pathogenic, likely pathogenic, VUS per ACMG/AMP guidelines) > Search first: ClinVar, ClinGen, ACMG/AMP guidelines, VarSome
Variant type/class (missense, frameshift, nonsense, splice-site, structural)
Allele frequency in population databases > Search first: gnomAD, 1000 Genomes, ExAC, TOPMed, dbSNP
Somatic vs germline origin > Search first: COSMIC (somatic), ClinVar, ICGC, TCGA
Functional consequences (loss of function, gain of function, dominant negative)
Modifier Genes: Genes that modify disease severity or expression
Epigenetic Information: DNA methylation, histone modifications, chromatin changes affecting disease

Search first: ENCODE, Roadmap Epigenomics, MethBase, DiseaseMeth
Chromosomal Abnormalities: Large-scale genetic changes (aneuploidy, translocations, inversions)

Search first: DECIPHER, ClinVar, ECARUCA, UCSC Genome Browser

5. Environmental Information

Environmental Factors: Non-genetic contributing factors (toxins, radiation, pollution, occupational exposure)

Search first: CTD (Comparative Toxicogenomics Database), TOXNET, PubMed, EPA databases
Lifestyle Factors: Behavioral factors (smoking, diet, exercise, alcohol consumption)

Search first: CDC databases, WHO, PubMed, NHANES
Infectious Agents: If applicable, pathogens causing or triggering disease (bacteria, viruses, fungi, parasites)

Search first: NCBI Taxonomy, ViPR, BV-BRC, MicrobeDB, GIDEON

6. Mechanism / Pathophysiology

Molecular Pathways: Specific signaling cascades or biochemical pathways involved (Wnt, MAPK, mTOR, PI3K-AKT, etc.)

Search first: KEGG, Reactome, WikiPathways, PathBank, BioCyc
Cellular Processes: Cell-level mechanisms (apoptosis, autophagy, cell cycle dysregulation, inflammation, etc.)

Search first: Gene Ontology (GO), Reactome, KEGG, PubMed
Protein Dysfunction: How protein structure or function is altered (misfolding, aggregation, loss of function, gain of function)

Search first: UniProt, PDB (Protein Data Bank), InterPro, Pfam, AlphaFold
Metabolic Changes: Alterations in metabolic processes (energy metabolism, lipid metabolism, amino acid metabolism)

Search first: KEGG, BioCyc, HMDB (Human Metabolome Database), BRENDA
Immune System Involvement: Role of immune response (autoimmunity, immunodeficiency, chronic inflammation)

Search first: ImmPort, Immunome Database, IEDB, Gene Ontology
Tissue Damage Mechanisms: How tissues/ are injured (oxidative stress, ischemia, fibrosis, necrosis)

Search first: PubMed, Gene Ontology, Reactome
Biochemical Abnormalities: Specific molecular defects (enzyme deficiencies, receptor dysfunction, ion channel defects)

Search first: BRENDA, UniProt, KEGG, OMIM, PubMed
Epigenetic Changes: DNA methylation, histone modifications affecting gene expression in disease

Search first: ENCODE, Roadmap Epigenomics, MethBase, DiseaseMeth
Molecular Profiling (if available):
Transcriptomics/gene expression changes > Search first: GEO (Gene Expression Omnibus), ArrayExpress, GTEx, Human Cell Atlas, SRA
Proteomics findings > Search first: PRIDE, ProteomeXchange, Human Protein Atlas, STRING, BioGRID
Metabolomics signatures > Search first: MetaboLights, Metabolomics Workbench, HMDB, METLIN
Lipidomics alterations > Search first: LIPID MAPS, SwissLipids, LipidHome, Metabolomics Workbench
Genomic structural features > Search first: UCSC Genome Browser, Ensembl, NCBI, dbVar, DGV
Advanced Technologies (if applicable):
Single-cell analysis findings (cell-type specific mechanisms, cellular heterogeneity) > Search first: Human Cell Atlas, Single Cell Portal, GEO, CELLxGENE
Spatial transcriptomics findings > Search first: GEO, Spatial Research, Vizgen, 10x Genomics data
Multi-omics integration results > Search first: TCGA, ICGC, cBioPortal, LinkedOmics, PubMed
Functional genomics screens (CRISPR, RNAi) > Search first: DepMap, GenomeRNAi, PubMed, BioGRID ORCS

For each mechanism, describe: - The causal chain from initial trigger to clinical manifestation - Which mechanisms are upstream vs downstream - What cell types and biological processes are involved - Suggest GO terms for biological processes and CL terms for cell types

7. Anatomical Structures Affected

Organ Level:
Primary organs directly affected
Secondary organ involvement (complications, secondary effects)
Body systems involved (cardiovascular, nervous, digestive, respiratory, endocrine, etc.)

Search first: Uberon, FMA (Foundational Model of Anatomy), OMIM, HPO, ICD-11, MeSH, SNOMED CT
Tissue and Cell Level:
Specific tissue types affected (epithelial, connective, muscle, nervous)
Specific cell populations targeted (with Cell Ontology terms)

Search first: Uberon, Human Protein Atlas, Cell Ontology, Human Cell Atlas, CellMarker, PanglaoDB
Subcellular Level:
Cellular compartments involved (mitochondria, nucleus, ER, lysosomes) (with GO Cellular Component terms)

Search first: Gene Ontology (Cellular Component), UniProt, Human Protein Atlas
Localization:
Specific anatomical sites (with UBERON terms) > Search first: FMA, Uberon, NeuroNames (for brain), SNOMED CT
Lateralization (unilateral, bilateral, asymmetric) > Search first: HPO, clinical literature, imaging databases

8. Temporal Development

Onset:
Typical age of onset (congenital, pediatric, adult, geriatric)
Onset pattern (acute, subacute, chronic, insidious)

Search first: OMIM, Orphanet, HPO, PubMed
Progression:
Disease stages (early, intermediate, advanced, end-stage) > Search first: Cancer Staging Manual (AJCC), WHO classifications, PubMed
Progression rate (rapid, slow, variable)
Disease course pattern (episodic, relapsing-remitting, progressive, stable)
Disease duration (self-limited, chronic lifelong)

Search first: Disease registries, longitudinal cohort databases, natural history studies, PubMed, Orphanet, OMIM
Patterns:
Remission patterns (spontaneous, treatment-induced) > Search first: Clinical trial databases, disease registries, PubMed
Critical periods (time windows of vulnerability or opportunity for intervention) > Search first: PubMed, developmental biology databases, clinical guidelines

9. Inheritance and Population

Epidemiology:
Prevalence (cases per 100,000 at given time)
Incidence (new cases per 100,000 per year)

Search first: Orphanet, CDC, WHO, GBD (Global Burden of Disease), national registries, SEER, disease registries
For Genetic Etiology:
Inheritance pattern (AD, AR, X-linked, mitochondrial, multifactorial, polygenic) > Search first: OMIM, Orphanet, ClinVar, GTR (Genetic Testing Registry)
Penetrance (complete, incomplete, age-dependent) > Search first: ClinVar, OMIM, PubMed, ClinGen
Expressivity (variable, consistent) > Search first: OMIM, ClinVar, PubMed
Genetic anticipation (increasing severity in successive generations) > Search first: OMIM, PubMed (especially for repeat expansion disorders)
Germline mosaicism > Search first: ClinVar, OMIM, genetic counseling literature, PubMed
Founder effects (population-specific mutations) > Search first: gnomAD, population genetics databases, PubMed
Consanguinity role > Search first: OMIM, population studies, genetic counseling resources
Carrier frequency > Search first: gnomAD, carrier screening databases, GeneReviews, GTR
Population Demographics:
Affected populations (ethnic or demographic groups with higher prevalence) > Search first: gnomAD, 1000 Genomes, PAGE Study, PubMed, population registries
Geographic distribution (endemic areas, regional variation) > Search first: WHO, CDC, GBD, Orphanet, geographic epidemiology databases
Geographic distribution of specific variants
Sex ratio (male:female) > Search first: Disease registries, OMIM, PubMed, epidemiological databases
Age distribution of affected individuals > Search first: CDC, disease registries, SEER, Orphanet

10. Diagnostics

Clinical Tests:
Laboratory tests (blood, urine, tissue chemistry, specific enzyme assays) > Search first: LOINC, LabTests Online, PubMed
Biomarkers (proteins, metabolites, genetic markers, circulating biomarkers) > Search first: FDA Biomarker List, BEST (Biomarkers, EndpointS, and other Tools), PubMed
Imaging studies (X-ray, CT, MRI, PET, ultrasound) > Search first: RadLex, DICOM, Radiopaedia, imaging databases
Functional tests (pulmonary function, cardiac stress tests) > Search first: LOINC, clinical guidelines, PubMed
Electrophysiology (EEG, EMG, ECG, nerve conduction studies) > Search first: LOINC, clinical neurophysiology databases, PubMed
Biopsy findings (histopathology, immunohistochemistry) > Search first: SNOMED CT, College of American Pathologists resources, PubMed
Pathology findings (microscopic examination) > Search first: SNOMED CT, Digital Pathology databases, PubMed
Genetic Testing:

Search first: GTR (Genetic Testing Registry), GeneReviews, ClinGen
Overview of recommended genetic testing approach
Whole genome sequencing (WGS) utility > Search first: GTR, ClinVar, GEL (Genomics England), gnomAD
Whole exome sequencing (WES) utility > Search first: GTR, ClinVar, OMIM, GeneMatcher
Gene panels (which panels, which genes) > Search first: GTR, ClinVar, laboratory-specific databases
Single gene testing > Search first: GTR, ClinVar, OMIM, GeneReviews
Chromosomal microarray (CMA) > Search first: DECIPHER, ClinVar, dbVar, ECARUCA
Karyotyping > Search first: Chromosome Abnormality Database, ClinVar, cytogenetics resources
FISH > Search first: ClinVar, cytogenetics databases, PubMed
Mitochondrial DNA testing > Search first: MITOMAP, MSeqDR, ClinVar, GTR
Repeat expansion testing > Search first: GTR, ClinVar, repeat expansion databases, PubMed
Omics-Based Diagnostics (if applicable):
RNA sequencing / transcriptomics > Search first: GEO, ArrayExpress, GTEx, RNA-seq databases
Proteomics > Search first: PRIDE, ProteomeXchange, FDA Biomarker database
Metabolomics > Search first: MetaboLights, Metabolomics Workbench, HMDB
Epigenomics > Search first: GEO, ENCODE, Roadmap Epigenomics, MethBase
Liquid biopsy > Search first: COSMIC, ClinVar, liquid biopsy databases, PubMed
Clinical Criteria:
Standardized diagnostic criteria (DSM, ICD, society guidelines) > Search first: DSM-5, ICD-11, clinical society guidelines, UpToDate
Differential diagnosis (other conditions to rule out, with distinguishing features) > Search first: DynaMed, UpToDate, clinical decision support systems
Screening:
Screening methods for asymptomatic individuals (newborn screening, carrier screening, cascade screening) > Search first: ACMG recommendations, CDC newborn screening, GTR

11. Outcome/Prognosis

Survival and Mortality:
Survival rate (5-year, 10-year, overall) > Search first: SEER, cancer registries, disease-specific registries, PubMed
Life expectancy (with and without treatment if applicable) > Search first: Orphanet, disease registries, actuarial databases, PubMed
Mortality rate > Search first: CDC, WHO, GBD, national mortality databases
Disease-specific mortality (deaths directly attributable to disease) > Search first: Disease registries, CDC Wonder, GBD, PubMed
Morbidity and Function:
Morbidity (disease-related disability and health impacts) > Search first: GBD, WHO, disability databases, PubMed
Disability outcomes (long-term functional impairments) > Search first: ICF (International Classification of Functioning), disability registries
Quality of life measures (EQ-5D, SF-36, PROMIS, disease-specific tools) > Search first: EQ-5D database, SF-36, PROMIS, PubMed
Disease Course:
Complications (secondary problems: infections, organ failure, etc.) > Search first: ICD codes, disease registries, clinical databases, PubMed
Recovery potential (likelihood and extent of recovery, with vs without treatment) > Search first: Natural history studies, rehabilitation databases, PubMed
Prediction:
Prognostic factors (age, disease severity, biomarkers, treatment response) > Search first: Prognostic models databases, clinical calculators, PubMed
Prognostic biomarkers (molecular markers predicting disease course) > Search first: FDA Biomarker database, PubMed, cancer prognostic databases

12. Treatment

Pharmacotherapy:
Pharmacological treatments (drug names, drug classes, mechanisms of action) > Search first: DrugBank, RxNorm, ATC classification, DailyMed, FDA databases
Pharmacogenomics (how genetic variants affect drug metabolism, efficacy, toxicity) > Search first: PharmGKB, CPIC (Clinical Pharmacogenetics), FDA Table of PGx Biomarkers
Advanced Therapeutics:
Gene therapy (viral vectors, CRISPR, gene replacement, gene editing) > Search first: ClinicalTrials.gov, FDA gene therapy database, ASGCT resources
Cell therapy (stem cell transplant, CAR-T, cellular therapeutics) > Search first: ClinicalTrials.gov, FDA cell therapy database, FACT standards
RNA-based therapies (ASOs, siRNA, mRNA therapies) > Search first: ClinicalTrials.gov, FDA approvals, PubMed
Targeted therapies (treatments directed at specific molecular targets) > Search first: My Cancer Genome, OncoKB, ClinicalTrials.gov, FDA approvals
Immunotherapies (checkpoint inhibitors, monoclonal antibodies) > Search first: Cancer Immunotherapy Database, FDA approvals, ClinicalTrials.gov
Surgical and Interventional:
Surgical interventions (types of surgery, timing, outcomes) > Search first: CPT codes, surgical registries, clinical guidelines, PubMed
Supportive and Rehabilitative:
Supportive care (symptom management, pain control, nutrition) > Search first: Clinical guidelines, Cochrane Library, PubMed
Rehabilitation (physical therapy, occupational therapy, speech therapy) > Search first: Rehabilitation medicine databases, clinical guidelines, PubMed
Experimental:
Experimental treatments in clinical trials (with NCT identifiers if available) > Search first: ClinicalTrials.gov, EU Clinical Trials Register, WHO ICTRP
Treatment Outcomes:
Treatment response rates > Search first: Clinical trial databases, FDA reviews, systematic reviews, PubMed
Side effects and adverse events > Search first: FDA Adverse Event Reporting System (FAERS), MedWatch, PubMed
Treatment Strategy:
Treatment algorithms (clinical pathways, decision trees) > Search first: Clinical practice guidelines, NCCN Guidelines, UpToDate
Combination therapies > Search first: ClinicalTrials.gov, treatment guidelines, PubMed
Personalized medicine approaches (genotype-guided treatment) > Search first: My Cancer Genome, CIViC, PharmGKB, precision medicine databases

For each treatment, suggest MAXO (Medical Action Ontology) terms where applicable.

13. Prevention

Prevention Levels:
Primary prevention (preventing disease occurrence: vaccination, risk factor modification) > Search first: CDC, WHO, USPSTF recommendations, Cochrane Library
Secondary prevention (early detection and treatment: screening programs, early intervention) > Search first: USPSTF, CDC screening guidelines, WHO
Tertiary prevention (preventing complications in those with disease) > Search first: Clinical guidelines, disease management protocols, PubMed
Immunization: Vaccine strategies (if applicable)

Search first: CDC vaccine schedules, WHO immunization, FDA vaccine database
Screening and Early Detection:
Screening programs (population-based: newborn screening, cancer screening) > Search first: CDC screening programs, USPSTF, cancer screening databases
Genetic screening (carrier screening, preimplantation genetic diagnosis, prenatal testing) > Search first: ACMG recommendations, ACOG guidelines, GTR
Risk stratification (identifying high-risk individuals for targeted prevention) > Search first: Risk prediction models, clinical calculators, PubMed
Behavioral Interventions: Lifestyle modifications to reduce risk

Search first: CDC, WHO, behavioral intervention databases, Cochrane Library
Counseling: Genetic counseling (risk assessment, family planning guidance)

Search first: NSGC resources, ACMG guidelines, GeneReviews
Public Health:
Public health interventions (sanitation, vector control, health education) > Search first: CDC, WHO, public health databases, PubMed
Environmental interventions (reducing environmental risk factors) > Search first: EPA databases, WHO environmental health, PubMed
Prophylaxis: Preventive medications or procedures

Search first: Clinical guidelines, FDA approvals, PubMed

14. Other Species / Natural Disease

Taxonomy: Species affected (with NCBI Taxon identifiers)

Search first: NCBI Taxonomy
Breed: Specific breeds affected (with VBO identifiers if applicable)

Search first: VBO (Vertebrate Breed Ontology)
Gene: Orthologous genes in other species (with NCBI Gene IDs)

Search first: NCBI Gene
Natural Disease:
Naturally occurring disease in other species (companion animals, wildlife) > Search first: OMIA (Online Mendelian Inheritance in Animals), VetCompass, PubMed
Veterinary relevance and importance in animal health > Search first: OMIA, veterinary databases, PubMed
Comparative Biology:
Comparative pathology (similarities and differences across species) > Search first: OMIA, comparative pathology databases, PubMed
Evolutionary conservation of disease mechanisms > Search first: HomoloGene, OrthoMCL, Alliance of Genome Resources
Transmission (if applicable):
Zoonotic potential > Search first: CDC zoonotic diseases, WHO zoonoses, GIDEON
Cross-species susceptibility > Search first: NCBI Taxonomy, veterinary databases, PubMed

15. Model Organisms

Model Types:
Model organism type (mammalian, invertebrate, cellular, in vitro) > Search first: Alliance of Genome Resources, model organism databases
Specific model systems (mouse, rat, zebrafish, Drosophila, C. elegans, yeast, cell lines, organoids, iPSCs) > Search first: MGI, RGD, ZFIN, FlyBase, WormBase, SGD, ATCC, Cellosaurus
Induced models (drug treatment, surgical intervention, environmental manipulation) > Search first: MGI, model organism databases, PubMed
Genetic Models:
Types available (knockout, knock-in, transgenic, conditional, humanized) > Search first: MGI, IMPC, KOMP, EuMMCR, IMSR
Model Characteristics:
Phenotype recapitulation (how well model reproduces human disease features) > Search first: Model organism databases, comparative studies, PubMed
Model limitations (aspects of human disease not captured) > Search first: Model organism databases, PubMed, review articles
Applications:
Research applications (what aspects of disease can be studied) > Search first: Model organism databases, PubMed
Resources:
Model databases > Search first: MGI, RGD, ZFIN, FlyBase, WormBase, IMSR, EMMA, MMRRC

Citation Requirements

Cite primary literature (PMID preferred) for all mechanistic and clinical claims
Prioritize recent reviews and landmark papers
Include direct quotes from abstracts where possible to support key statements
Distinguish evidence source types: human clinical, model organism, in vitro, computational

Output Format

Structure your response as a comprehensive narrative organized by the sections above. For each section, provide: - Factual content with specific details (numbers, percentages, gene names, variant nomenclature) - Ontology term suggestions (HPO, GO, CL, UBERON, CHEBI, MAXO, MONDO) where applicable - Evidence citations with PMIDs - Direct quotes from abstracts to support key claims - Clear indication when information is not available or not applicable for this disease

This report will be used to populate a disease knowledge base entry with: - Pathophysiology descriptions with causal chains - Gene/protein annotations (HGNC, GO terms) - Phenotype associations (HP terms) with frequencies - Cell type involvement (CL terms) - Anatomical locations (UBERON terms) - Chemical entities (CHEBI terms) - Treatment annotations (MAXO terms) - Evidence items with PMIDs and exact abstract quotes - Epidemiology, prognosis, diagnostic, and prevention information - Animal model descriptions with phenotype recapitulation details

Comprehensive research report: Meningeal Melanocytoma

Target disease

Disease name: Meningeal melanocytoma
Category: Primary meningeal melanocytic tumor (circumscribed primary CNS melanocytic neoplasm)
MONDO/MeSH/ICD/Orphanet/OMIM identifiers: Not reliably retrievable from the available tool evidence in this run; below, the report is therefore grounded in peer‑reviewed WHO-aligned literature and ClinicalTrials.gov records rather than ontology database exports. (pellerino2024primarymeningealmelanocytic pages 2-3, pellerino2024primarymeningealmelanocytic pages 1-2)

1. Disease information

1.1 Definition and current classification

Meningeal melanocytoma is a circumscribed melanocytic tumor of the meninges with a bland histologic appearance. In the WHO CNS tumor framework (WHO CNS 2021 / 5th edition), primary meningeal melanocytic tumors are described as either circumscribed solitary/bulky lesions or diffuse/multifocal leptomeningeal dissemination. Within the circumscribed group, melanocytoma represents the benign/differentiated end of the spectrum, with intermediate-grade melanocytoma and meningeal melanoma representing higher-grade categories. (pellerino2024primarymeningealmelanocytic pages 1-2, pellerino2024primarymeningealmelanocytic pages 3-5)

WHO-aligned histologic criteria summarized in EURACAN review material include approximate mitotic thresholds: melanocytoma typically shows <0.5 mitoses/mm² (≈ <1 mitosis/10 HPF) and no necrosis or CNS parenchymal invasion; intermediate-grade melanocytoma is associated with 0.5–1.5 mitoses/mm² and/or CNS invasion; meningeal melanoma is associated with >1.5 mitoses/mm², marked atypia and necrosis. (pellerino2024primarymeningealmelanocytic pages 3-5, pellerino2024primarymeningealmelanocytic pages 6-7)

1.2 Synonyms and related terms

Commonly used alternative names and related entities in the literature include: - Primary meningeal melanocytic tumor (umbrella term) (pellerino2024primarymeningealmelanocytic pages 1-2) - Leptomeningeal melanocytoma / meningeal melanocytoma (ricchizzi2022howshouldwe pages 1-3) - Spinal meningeal melanocytoma / intracranial meningeal melanocytoma (tsai2023recurrentspinalmeningeal pages 1-3, ricchizzi2022howshouldwe pages 3-5) - Related diffuse entities (context): diffuse meningeal melanocytosis and diffuse meningeal melanomatosis (pellerino2024primarymeningealmelanocytic pages 2-3, pellerino2024primarymeningealmelanocytic pages 3-5)

1.3 Evidence sources and aggregation

Evidence is largely aggregated from case reports and small cohorts due to the rarity of the disease; EURACAN explicitly highlights that these tumors are not well captured by prospective registries, leading to weak evidence for correlations between clinical course, imaging, and molecular features. (pellerino2024primarymeningealmelanocytic pages 1-2)

Direct abstract quote (EURACAN review): “Primary meningeal melanocytic tumors are ultra-rare entities…” and the review was based on a literature search “from January 1985 to December 2023.” (pellerino2024primarymeningealmelanocytic pages 1-2)

2. Etiology

2.1 Causal factors / origin

Primary meningeal melanocytic tumors arise from melanocytes of neural crest origin that populate the leptomeninges (and possibly choroid plexus melanoblasts during embryogenesis). (pellerino2024primarymeningealmelanocytic pages 1-2)

2.2 Risk factors

Robust environmental risk factors are not established in the retrieved evidence. However, several clinical association contexts recur: - Neurocutaneous melanosis (NCM): a rare congenital disorder with abnormal CNS nevomelanocyte aggregates and large/giant congenital melanocytic nevi. NCM has estimated prevalence 1/50,000–1/200,000 and incidence 0.5–2 per 100,000 person-year; approximately 10–15% of NCM patients develop meningeal melanocytomas. (pellerino2024primarymeningealmelanocytic pages 2-3) - BAP1 tumor predisposition syndrome (germline BAP1): associated with higher risk of meningeal/uveal/cutaneous melanoma and other cancers; primary meningeal melanocytic tumors can occur in this syndrome. (pellerino2024primarymeningealmelanocytic pages 2-3)

2.3 Protective factors and gene–environment interactions

No protective factors or gene–environment interaction data were identified in the retrieved evidence; this is a recognized gap consistent with the ultra-rare nature of the disease. (pellerino2024primarymeningealmelanocytic pages 1-2)

3. Phenotypes (clinical presentation)

3.1 Typical presentations and symptomatology

Clinical presentation depends on tumor location and mass effect. - Intracranial/diffuse disease: may present with seizures, increased intracranial pressure/hydrocephalus, focal deficits (motor/sensory), visual symptoms (scotoma/blurred vision/field deficits), cerebellar signs, gait disturbance and ataxia. (pellerino2024primarymeningealmelanocytic pages 3-5) - Spinal involvement: para- or tetraparesis, sensory level deficits, radicular and/or back pain, urinary/bowel disturbances. (pellerino2024primarymeningealmelanocytic pages 3-5)

Case-report level phenotypes include progressive myelopathy and sphincter dysfunction (e.g., urinary retention) in spinal disease. (tsai2023recurrentspinalmeningeal pages 1-3)

3.2 Suggested HPO phenotype terms (non-exhaustive)

Based on reported symptom patterns: - Seizures HP:0001250 (pellerino2024primarymeningealmelanocytic pages 3-5) - Increased intracranial pressure HP:0002516 / Hydrocephalus HP:0000238 (pellerino2024primarymeningealmelanocytic pages 3-5) - Headache HP:0002315 (pellerino2024primarymeningealmelanocytic pages 3-5) - Ataxia HP:0001251 / Gait ataxia HP:0002066 (pellerino2024primarymeningealmelanocytic pages 3-5) - Visual field defect HP:0001123 / Blurred vision HP:0000622 (pellerino2024primarymeningealmelanocytic pages 3-5) - Paraparesis HP:0003401 / Tetraparesis HP:0002273 (pellerino2024primarymeningealmelanocytic pages 3-5) - Radicular pain HP:0001284 / Back pain HP:0003418 (pellerino2024primarymeningealmelanocytic pages 3-5) - Urinary retention HP:0000017 / Neurogenic bladder HP:0000010 (tsai2023recurrentspinalmeningeal pages 1-3)

3.3 Demographics and frequency of presentations

A pooled analysis of 201 English-language cases (1972–2022) reported a median age of onset 38 years (range 28 weeks–79 years) and male predominance (107/180; 59.4%) among cases with available sex data. (ricchizzi2022howshouldwe pages 3-5)

4. Genetic / molecular information

4.1 Key driver alterations (current understanding)

Circumscribed primary meningeal melanocytic tumors (including melanocytoma) commonly show mutually exclusive activating hotspot mutations in the Gαq pathway: - GNAQ and GNA11, and also PLCB4 and CYSLTR2 in subsets. (pellerino2024primarymeningealmelanocytic pages 6-7)

In EURACAN’s synthesis, GNAQ/GNA11 are described as the most frequent (reported around ~60–70% for circumscribed tumors in the excerpt). (pellerino2024primarymeningealmelanocytic pages 6-7)

Diffuse meningeal melanocytic tumors (often in the NCM context) more often harbor NRAS and less commonly BRAF alterations. (pellerino2024primarymeningealmelanocytic pages 1-2, pellerino2024primarymeningealmelanocytic pages 6-7)

4.2 Mutation frequencies and diagnostic utility (primary literature)

A Brain Pathology review with molecular focus reports approximate frequencies in primary leptomeningeal melanocytic neoplasms: GNAQ mutations ~39% in melanocytomas and ~17% in primary leptomeningeal melanomas; GNA11 mutations ~17% in melanocytomas and ~29% in primary leptomeningeal melanomas (historical series summarized). (kusters‐vandevelde2015primarymelanocytictumors pages 7-8)

4.3 Epigenomics and methylation profiling

DNA methylation profiling can help distinguish melanocytoma, melanoma, and melanotic schwannoma/MMNST as entity-specific methylation groups, supporting integrated diagnosis beyond morphology. (koelsche2015melanotictumorsof pages 1-2, koelsche2015melanotictumorsof pages 2-3)

In Koelsche et al. (Brain Pathology 2015), methylation profiling segregated tumors into methylation groups corresponding to melanotic schwannoma, melanocytoma, and melanoma, and recurrent hotspot GNAQ/GNA11 mutations were concentrated in the melanocytoma methylation group, while TERT promoter and NRAS/BRAF/KIT activating mutations were restricted to the melanoma methylation group. (koelsche2015melanotictumorsof pages 2-3)

A contemporary observational cohort study protocol (NCT05984108) describes use of the Heidelberg classifier v12.5 with a “melanocytoma” methylation class (grouping melanocytoma, meningeal melanoma, uveal melanoma), along with separate methylation classes for melanoma metastases and MMNST; it notes no methylation class yet exists for diffuse melanocytosis/melanomatosis. (NCT05984108 chunk 1)

4.4 Pathway-level mechanism (actionable biology)

Mechanistically, oncogenic GNAQ/GNA11 activate downstream signaling including PKC→MAPK and the Hippo–YAP axis; GNAQ Q209 can activate YAP. This provides a rationale for targeting downstream nodes (PKC, MAPK, YAP) rather than GNAQ/GNA11 directly (no direct inhibitors referenced in the excerpt). (kusters‐vandevelde2015primarymelanocytictumors pages 10-11)

4.5 Suggested ontology mappings

Candidate causal/driver genes (HGNC): GNAQ, GNA11, PLCB4, CYSLTR2; NRAS; BRAF; BAP1; SF3B1; EIF1AX. (pellerino2024primarymeningealmelanocytic pages 6-7, pellerino2024primarymeningealmelanocytic pages 1-2)
GO biological processes (suggested):
MAPK cascade GO:0000165 (kusters‐vandevelde2015primarymelanocytictumors pages 10-11)
Regulation of cell proliferation GO:0042127 (general; supported by oncogenic signaling rationale) (kusters‐vandevelde2015primarymelanocytictumors pages 10-11)
Hippo signaling GO:0035329 / YAP/TAZ signaling (mechanistic mention) (kusters‐vandevelde2015primarymelanocytictumors pages 10-11)
CL cell types (suggested): melanocyte CL:0000148 (tumor cell of origin) (pellerino2024primarymeningealmelanocytic pages 1-2)

5. Environmental information

No specific toxins, radiation, lifestyle, or infectious triggers were identified in the retrieved evidence for meningeal melanocytoma; most discussion centers on developmental/embryologic melanocyte distribution and genetic drivers. (pellerino2024primarymeningealmelanocytic pages 1-2)

6. Mechanism / pathophysiology

6.1 Causal chain (integrated view)

Neural crest–derived melanocytes populate leptomeningeal sites (posterior cranial base, foramen magnum, trigeminal cave) where melanocyte density is physiologically higher. (pellerino2024primarymeningealmelanocytic pages 2-3)
Acquisition of activating oncogenic mutations in GNAQ/GNA11 (and related Gαq pathway alterations) drives melanocytic neoplasia in the meningeal microenvironment. (pellerino2024primarymeningealmelanocytic pages 6-7, kusters‐vandevelde2015primarymelanocytictumors pages 10-11)
Downstream activation of PKC→MAPK and Hippo–YAP signaling contributes to proliferation/survival, yielding a circumscribed lesion with variable clinical mass-effect symptoms. (kusters‐vandevelde2015primarymelanocytictumors pages 10-11, pellerino2024primarymeningealmelanocytic pages 3-5)
Additional alterations (e.g., BAP1/SF3B1/EIF1AX, monosomy 3, complex CNV) may shift toward more aggressive behavior (intermediate-grade/melanoma spectrum), with higher recurrence/metastasis risk in a subset. (pellerino2024primarymeningealmelanocytic pages 3-5, ricchizzi2022howshouldwe pages 7-8)

6.2 Upstream vs downstream

Upstream: initiating mutations in GNAQ/GNA11/PLCB4/CYSLTR2 (circumscribed) or NRAS/BRAF (diffuse/NCM-associated). (pellerino2024primarymeningealmelanocytic pages 6-7)
Downstream: PKC/MAPK and YAP axis activation. (kusters‐vandevelde2015primarymelanocytictumors pages 10-11)

7. Anatomical structures affected

7.1 Primary sites

Leptomeninges (UBERON: leptomeninx), especially posterior cranial base, foramen magnum, trigeminal cave; also spinal leptomeninges. (pellerino2024primarymeningealmelanocytic pages 2-3, rades2004therapyofmeningeal pages 2-4)

7.2 Anatomic distribution statistics (pooled data)

In pooled 201-case analysis (where location data were available in 189 cases), approximately half were intracranial (101/189; 52.6%), with posterior fossa dominating intracranial sites (57/101; 56.4%) and thoracic/cervical spine dominating spinal sites (thoracic 39/78; 50%, cervical 26/78; 33.3%). (ricchizzi2022howshouldwe pages 3-5)

8. Temporal development

8.1 Onset and course

Meningeal melanocytoma is often a slow-growing lesion but can behave aggressively and recur even after gross total resection; malignant transformation is reported in case literature. (tsai2023recurrentspinalmeningeal pages 1-3, ricchizzi2022howshouldwe pages 1-3)

8.2 Progression, recurrence, and transformation

A modern pooled review reported malignant transformation in 18 patients, with 11 developing metastasis. (ricchizzi2022howshouldwe pages 1-3)
Follow-up across published cases is heterogeneous; median follow-up in the 201-case pooled analysis was 18 months (range few days–35 years). (ricchizzi2022howshouldwe pages 7-8)

9. Inheritance and population

9.1 Epidemiology

From EURACAN (published 10 Jul 2024, https://doi.org/10.3390/cancers16142508): - Meningeal melanocytomas and meningeal melanomas account for 0.06–0.1% of total meningeal tumors. (pellerino2024primarymeningealmelanocytic pages 2-3) - Estimated incidence of meningeal melanocytoma: 1/10,000,000 person-year. (pellerino2024primarymeningealmelanocytic pages 2-3)

Demographic pattern varies by series. In the Rades pooled therapy comparison (89 patients), median age was 45 years (range 9–75) with 49 females/40 males. (rades2004therapyofmeningeal pages 2-4)

9.2 Germline inheritance

Meningeal melanocytoma itself is not established as a Mendelian inherited disease in the retrieved sources; however, it can occur in the context of germline BAP1 tumor predisposition syndrome. (pellerino2024primarymeningealmelanocytic pages 2-3)

10. Diagnostics

10.1 Imaging

MRI often shows T1 hyperintensity and T2 hypointensity due to melanin paramagnetic effects; susceptibility/blooming may reflect microbleeds and intratumoral hemorrhage can evolve over ~3 months. (pellerino2024primarymeningealmelanocytic pages 7-10)
In pooled MM review, MM were described as isointense to hyperintense on T1, isointense to hypointense on T2, with heterogeneous contrast enhancement; CT lesions were well-defined, isodense to hyperdense, contrast-enhancing. (ricchizzi2022howshouldwe pages 1-3)
Imaging can suggest melanocytic nature and circumscribed vs diffuse pattern but cannot reliably determine aggressiveness or differentiate primary vs metastatic lesions without systemic evaluation. (pellerino2024primarymeningealmelanocytic pages 11-12, pellerino2024primarymeningealmelanocytic pages 7-10)

10.2 Histopathology and IHC

Canonical IHC phenotype includes positivity for S-100, HMB-45, Melan-A, with supportive negatives including EMA and GFAP/cytokeratin in many series; these panels help differentiate from meningioma and other mimics. (rades2004therapyofmeningeal pages 1-2, kusters‐vandevelde2015primarymelanocytictumors pages 5-6)

10.3 Proliferation indices and thresholds

WHO-aligned mitotic thresholds are summarized above (mitoses/mm²) for melanocytoma vs intermediate vs melanoma. (pellerino2024primarymeningealmelanocytic pages 3-5)
A pooled MM therapeutic meta-analysis emphasizes Ki-67/MIB1 thresholds for clinical stratification: 5–10% suggested for intermediate-grade and >10% for malignant transformation. (ricchizzi2022howshouldwe pages 7-8)

10.4 Differential diagnosis (critical)

Key differentials include: - Meningioma (dural-based, imaging mimic) (kusters‐vandevelde2015primarymelanocytictumors pages 5-6, pellerino2024primarymeningealmelanocytic pages 11-12) - Metastatic melanoma (requires systemic exclusion) (pellerino2024primarymeningealmelanocytic pages 7-10, NCT05984108 chunk 1) - Malignant melanotic peripheral nerve sheath tumor (MMNST; formerly melanotic schwannoma), often associated with Carney complex and can co-express S100/SOX10 with melanocytic markers; may involve PRKAR1A. (pellerino2024primarymeningealmelanocytic pages 11-12, NCT05984108 chunk 1)

10.5 Recommended systemic workup to exclude metastasis

EURACAN review material recommends that imaging and systemic evaluation should exclude metastatic cutaneous melanoma, including whole-body imaging (18F-FDG PET-CT), gastrointestinal endoscopy, and skin and eye examinations, plus spine MRI to evaluate neuraxial spread. (pellerino2024primarymeningealmelanocytic pages 7-10)

10.6 Molecular diagnostics / methylation

Detection of GNAQ/GNA11/PLCB4/CYSLTR2 and methylation profiling supports primary CNS origin and helps separate from metastatic melanoma (often HRAS/KRAS/BRAF/KIT) and MMNST. (pellerino2024primarymeningealmelanocytic pages 11-12, NCT05984108 chunk 1)

11. Outcome / prognosis

11.1 Surgical extent and radiotherapy influence outcomes

A pooled outcomes analysis in Cancer (Rades et al., published online 23 Apr 2004; https://doi.org/10.1002/cncr.20296) compared strategies: - 5-year local control: complete resection (CTR) 80%, CTR + RT 100%, incomplete resection (ITR) + RT 72%, ITR alone 18%. (rades2004therapyofmeningeal pages 1-2) - 5-year survival: CTR 100%, CTR + RT 100%, ITR + RT 100%, vs ITR alone 46%. (rades2004therapyofmeningeal pages 1-2) - RT dose signal after ITR: 45–55 Gy associated with 5-year local control 86% vs 27% after 30–40 Gy (trend; small numbers). (rades2004therapyofmeningeal pages 2-4)

11.2 Recurrence and metastasis

In the Rades pooled analysis, overall recurrence was 37% (33/89), with recurrence 24% after CTR, 78% after ITR, and improved recurrence after ITR+RT (24%) (small CTR+RT group had 0% recurrence). (rades2004therapyofmeningeal pages 2-4)
In the 201-case pooled analysis, malignant transformation occurred in 18 patients and 11 developed metastasis. (ricchizzi2022howshouldwe pages 1-3)

12. Treatment

12.1 Local therapy (real-world standard)

Surgery: Gross-total resection is consistently positioned as first-line for circumscribed meningeal melanocytoma and associated with best recurrence-free outcomes. (pellerino2024primarymeningealmelanocytic pages 1-2, ricchizzi2022howshouldwe pages 7-8)

Radiotherapy: Evidence supports benefit after incomplete/subtotal resection and in recurrence; dose regimens in literature vary. - In Rades et al., adjuvant RT improved outcomes after incomplete resection; higher doses (45–55 Gy) appeared more favorable than 30–40 Gy in a small subset. (rades2004therapyofmeningeal pages 2-4) - Classen et al. (J Neuro-Oncol 2002; https://doi.org/10.1023/a:1015872207398) found recurrence after complete resection without RT in 3/21 (14.2%) and relapse after incomplete resection without RT in 5/9 (55.5%), with lower relapse after incomplete resection + RT (3/7; 42.9%); they advised total RT dose “not … less than 50–55 Gy” in their synthesis. (classen2002suprasellarmelanocytomaa pages 6-7)

Suggested MAXO terms (high level): - Surgical excision (gross total resection) MAXO:0001114 (conceptual mapping) - External beam radiotherapy MAXO:0000127 (conceptual mapping)

12.2 Systemic therapy (limited evidence; mostly extrapolated)

EURACAN emphasizes that prospective trials are lacking and systemic therapy evidence is mainly case reports. Reported regimens across primary meningeal melanocytic tumors include intrathecal chemotherapy (etoposide/cytarabine/topotecan) and systemic therapies such as interferon alpha, temozolomide, everolimus, trametinib, and immune checkpoint inhibitors (nivolumab ± ipilimumab). The overall benefit is described as limited/weak and median OS in aggressive contexts can be poor. (pellerino2024primarymeningealmelanocytic pages 11-12)

Ricchizzi et al. reported systemic therapy use in 11 pooled cases with radiotherapy; outcomes were poor (“in all patients but one, tumor growth was observed, and all patients but four died”). (ricchizzi2022howshouldwe pages 3-5)

13. Prevention

No established primary prevention measures were identified; given rarity and largely sporadic biology, prevention centers on management of associated syndromic contexts (e.g., surveillance in BAP1 tumor predisposition) and early recognition. Evidence in this run is insufficient for evidence-based prevention recommendations specific to meningeal melanocytoma. (pellerino2024primarymeningealmelanocytic pages 2-3)

14. Other species / natural disease

No veterinary/natural disease analogs were retrieved in this run.

15. Model organisms

Direct meningeal melanocytoma models were not retrieved; however, mechanistic modeling of GNAQ biology in melanocytic lineages is used broadly to understand Gαq-driven melanocytic neoplasms, and normal meningeal melanocyte distribution in mouse has been characterized as a substrate for understanding primary meningeal melanoma biology. (koelsche2015melanotictumorsof pages 1-2)

Recent developments and latest research (2023–2024 prioritized)

EURACAN 2024 consensus-style review (key update)

The most directly relevant 2024 synthesis is the EURACAN Ultra‑Rare Brain Tumors Task Force review (published 10 Jul 2024, DOI 10.3390/cancers16142508, URL https://doi.org/10.3390/cancers16142508), which consolidates WHO-aligned classification, molecular diagnostics, imaging strategy (whole neuroaxis imaging; systemic exclusion), and therapeutic evidence gaps, emphasizing the need for registries and integrated diagnosis. (pellerino2024primarymeningealmelanocytic pages 1-2)

Direct abstract quote: “Molecular analysis can detect specific mutations, including GNAQ, GNA11, SF3B1, EIF1AX, BAP1… whereas NRAS and BRAF mutations are typical for diffuse primary meningeal melanocytic tumors.” (pellerino2024primarymeningealmelanocytic pages 1-2)

Registry/diagnostic developments

The ClinicalTrials.gov observational study NCT05984108 (MelaMen) is explicitly designed to integrate clinical-radiologic-histologic-molecular characterization with methylation classifier use and long-term outcomes (OS/PFS up to 10 years), reflecting current real-world movement toward methylome-based integrated diagnosis. (NCT05984108 chunk 1)

Current applications and real-world implementations

Neurosurgical practice: gross-total resection when anatomically feasible; careful attention to involved dura and decompression principles similar to other dural-based tumors. (rades2004therapyofmeningeal pages 2-4, ricchizzi2022howshouldwe pages 7-8)
Adjuvant radiotherapy: used in subtotal resection, recurrence, or higher proliferative indices; dosing varies with historical evidence suggesting benefit in the 45–55 Gy range post-ITR. (rades2004therapyofmeningeal pages 2-4, classen2002suprasellarmelanocytomaa pages 6-7)
Integrated molecular pathology: targeted sequencing (GNAQ/GNA11/NRAS/BRAF etc.) and methylation profiling to resolve difficult differentials (metastatic melanoma, MMNST) and support diagnosis/prognosis. (NCT05984108 chunk 1, koelsche2015melanotictumorsof pages 2-3)

Expert opinion and analysis (authoritative sources)

EURACAN concludes evidence is weak and emphasizes multidisciplinary evaluation and referral to expert centers, and calls for shared platforms/registries given the ultra-rare status. (pellerino2024primarymeningealmelanocytic pages 1-2, pellerino2024primarymeningealmelanocytic pages 11-12)
Ricchizzi et al. propose a practical treatment guideline centered on resection extent and Ki-67 thresholds, while acknowledging major limitations (case-report heterogeneity; no tissue re-review to WHO 2021). (ricchizzi2022howshouldwe pages 3-5, ricchizzi2022howshouldwe pages 7-8)

Key statistics (recent pooled studies)

Incidence estimate: 1 per 10,000,000 person-year (EURACAN). (pellerino2024primarymeningealmelanocytic pages 2-3)
201-case pooled analysis: male predominance 59.4% and median age onset 38 years. (ricchizzi2022howshouldwe pages 3-5)
Malignant transformation: 18 patients; metastasis among transformed: 11 patients. (ricchizzi2022howshouldwe pages 1-3)
Rades pooled outcomes (n=89): 5-year local control and survival substantially worse after incomplete resection without RT. (rades2004therapyofmeningeal pages 1-2)

Embedded evidence table

Domain	Finding	Quantitative detail (if any)	Source (author-year)	DOI/URL	Evidence citation id
Disease frequency	Meningeal melanocytoma is ultra-rare and part of the spectrum of primary meningeal melanocytic tumors	Estimated incidence: 1/10,000,000 person-year; meningeal melanocytomas + meningeal melanomas account for 0.06–0.1% of total meningeal tumors	Pellerino et al. 2024	https://doi.org/10.3390/cancers16142508	(pellerino2024primarymeningealmelanocytic pages 1-2, pellerino2024primarymeningealmelanocytic pages 2-3)
Relative frequency in a retrospective CNS melanotic lesion cohort	Only a small fraction of CNS melanotic lesions met criteria for primary meningeal melanocytic tumors	4/116 cases (3.4%) in a Yale Cancer Center retrospective cohort (2001–2019)	Pellerino et al. 2024	https://doi.org/10.3390/cancers16142508	(pellerino2024primarymeningealmelanocytic pages 1-2)
Age distribution	Adult-predominant disease, especially mid-adulthood	Prevalence in 4th–5th decades; reported median age range 45.6–53.7 years	Pellerino et al. 2024	https://doi.org/10.3390/cancers16142508	(pellerino2024primarymeningealmelanocytic pages 2-3)
Age distribution in pooled MM cases	Disease of adults, but broad age range reported	Median age of onset 38 years; range 28 weeks to 79 years	Ricchizzi et al. 2022	https://doi.org/10.3390/cancers14235851	(ricchizzi2022howshouldwe pages 3-5)
Sex distribution in pooled MM cases	Male predominance in the 201-case pooled analysis	107/180 male (59.4%) vs 73/180 female (40.6%)	Ricchizzi et al. 2022	https://doi.org/10.3390/cancers14235851	(ricchizzi2022howshouldwe pages 3-5)
Demographics in Rades therapy cohort	Slight female predominance in older pooled treatment analysis	49 female, 40 male; median age 45 years (range 9–75)	Rades et al. 2004	https://doi.org/10.1002/cncr.20296	(rades2004therapyofmeningeal pages 2-4, rades2004therapyofmeningeal pages 1-2)
Common locations	Circumscribed lesions preferentially arise where leptomeningeal melanocytes are physiologically denser	Common sites: posterior cranial base, foramen magnum, trigeminal cave	Pellerino et al. 2024	https://doi.org/10.3390/cancers16142508	(pellerino2024primarymeningealmelanocytic pages 2-3)
Location distribution in pooled MM cases	About half intracranial; posterior fossa most common intracranial site; thoracic/cervical spine dominate spinal sites	Intracranial 101/189 (52.6%); posterior fossa 57/101 (56.4%); middle cranial fossa 11/101 (10.9%); sellar region 9/101 (8.9%); thoracic spine 39/78 (50%); cervical spine 26/78 (33.3%)	Ricchizzi et al. 2022	https://doi.org/10.3390/cancers14235851	(ricchizzi2022howshouldwe pages 3-5)
Location distribution in Rades cohort	Similar intracranial/spinal split with specific favored sites	46 spinal, 43 brain; intracranial: Meckel cave n=8, posterior fossa n=7; spinal: thoracic n=22, cervical n=17	Rades et al. 2004	https://doi.org/10.1002/cncr.20296	(rades2004therapyofmeningeal pages 2-4, rades2004therapyofmeningeal pages 1-2)
Rare presentations/associations	Intraventricular and intramedullary locations are unusual; association with neurocutaneous melanosis/BAP1 syndrome recognized	Neurocutaneous melanosis prevalence 1/50,000–1/200,000; incidence 0.5–2/100,000 person-year; ~10–15% of neurocutaneous melanosis patients develop meningeal melanocytomas	Pellerino et al. 2024	https://doi.org/10.3390/cancers16142508	(pellerino2024primarymeningealmelanocytic pages 2-3)
Imaging	Melanin-rich lesion pattern on MRI	Typical MRI: T1 isointense to hyperintense, T2 isointense to hypointense, with heterogeneous gadolinium enhancement	Ricchizzi et al. 2022	https://doi.org/10.3390/cancers14235851	(ricchizzi2022howshouldwe pages 1-3)
Imaging	CT appearance	Typically well-defined, isodense to hyperdense, contrast-enhancing lesion on CT	Ricchizzi et al. 2022; Rades et al. 2004	https://doi.org/10.3390/cancers14235851; https://doi.org/10.1002/cncr.20296	(ricchizzi2022howshouldwe pages 1-3, rades2004therapyofmeningeal pages 1-2)
Imaging limitation	Imaging can suggest melanocytic nature and circumscribed vs diffuse pattern, but cannot reliably determine aggressiveness or primary vs metastatic origin	Qualitative limitation; no validated imaging aggressiveness metric reported	Pellerino et al. 2024	https://doi.org/10.3390/cancers16142508	(pellerino2024primarymeningealmelanocytic pages 1-2, pellerino2024primarymeningealmelanocytic pages 11-12)
Histopathology	Bland circumscribed melanocytoma lacks necrosis and usually lacks CNS invasion; mitotic activity very low	Typical mitotic activity <0.5 mitoses/mm², equivalent to <1 mitosis/10 HPF	Pellerino et al. 2024	https://doi.org/10.3390/cancers16142508	(pellerino2024primarymeningealmelanocytic pages 3-5)
Pathology / gross appearance	Tumor is usually encapsulated and darkly pigmented	Macroscopy: encapsulated; color ranges from coal black to reddish brown/dark blue	Ricchizzi et al. 2022	https://doi.org/10.3390/cancers14235851	(ricchizzi2022howshouldwe pages 1-3)
Immunohistochemistry	Canonical melanocytic marker profile	Usually positive for S-100, HMB-45, Melan-A; variable vimentin and NSE	Ricchizzi et al. 2022; Rades et al. 2004	https://doi.org/10.3390/cancers14235851; https://doi.org/10.1002/cncr.20296	(ricchizzi2022howshouldwe pages 1-3, rades2004therapyofmeningeal pages 1-2)
Immunohistochemistry	Negative markers helpful in differential diagnosis	Usually negative for GFAP, EMA, and cytokeratin	Rades et al. 2004	https://doi.org/10.1002/cncr.20296	(rades2004therapyofmeningeal pages 1-2)
Molecular alterations: circumscribed tumors	Circumscribed primary meningeal melanocytic tumors show uveal/blue-nevus-like Gαq pathway alterations	Common: GNAQ, GNA11, PLCB4, CYSLTR2	Pellerino et al. 2024	https://doi.org/10.3390/cancers16142508	(pellerino2024primarymeningealmelanocytic pages 3-5, pellerino2024primarymeningealmelanocytic media 6f94701f)
Molecular alterations: aggressive behavior	Additional mutations/CNV indicate more aggressive biology in circumscribed tumors	BAP1, SF3B1, EIF1AX, monosomy 3, and complex copy-number variation associated with aggressive behavior	Pellerino et al. 2024; Ricchizzi et al. 2022	https://doi.org/10.3390/cancers16142508; https://doi.org/10.3390/cancers14235851	(pellerino2024primarymeningealmelanocytic pages 3-5, ricchizzi2022howshouldwe pages 7-8)
Molecular alterations: diffuse tumors	Diffuse leptomeningeal melanocytic tumors have a distinct molecular profile from circumscribed lesions	Often NRAS-mutated and rarely BRAF-mutated	Pellerino et al. 2024	https://doi.org/10.3390/cancers16142508	(pellerino2024primarymeningealmelanocytic pages 1-2, pellerino2024primarymeningealmelanocytic pages 3-5, pellerino2024primarymeningealmelanocytic media 6f94701f)
Differential molecular diagnosis	Molecular profile helps distinguish primary meningeal melanocytic tumors from metastatic melanoma and MMNST	Extracranial metastatic melanomas: nearly ~50% harbor HRAS/KRAS/BRAF/KIT; MMNST often linked to PRKAR1A mutation	Pellerino et al. 2024	https://doi.org/10.3390/cancers16142508	(pellerino2024primarymeningealmelanocytic pages 11-12)
Total pooled case count	Largest modern pooled English-language analysis of meningeal melanocytoma	201 cases included (1972–2022)	Ricchizzi et al. 2022	https://doi.org/10.3390/cancers14235851	(ricchizzi2022howshouldwe pages 1-3, ricchizzi2022howshouldwe pages 3-5)
Treatment distribution in pooled MM cases	Surgery overwhelmingly dominant first-line treatment	Surgery in 179/186 (96.2%) with treatment data available	Ricchizzi et al. 2022	https://doi.org/10.3390/cancers14235851	(ricchizzi2022howshouldwe pages 3-5)
Surgical extent in pooled MM cases	Roughly equal mix of gross-total and partial resection among surgically treated patients	Gross-total resection 89/179 (49.7%); partial resection 73/179 (40.7%)	Ricchizzi et al. 2022	https://doi.org/10.3390/cancers14235851	(ricchizzi2022howshouldwe pages 3-5)
Adjuvant RT use in pooled MM cases	RT used selectively after total or partial resection	Total resection alone 81/179 (45.3%); total resection + RT 8/179 (4.5%); partial resection alone 45/179 (25.1%); partial resection + RT 24/179 (13.4%)	Ricchizzi et al. 2022	https://doi.org/10.3390/cancers14235851	(ricchizzi2022howshouldwe pages 3-5)
Systemic therapy in pooled MM cases	Chemo-/immunotherapy showed little clear benefit in pooled case literature	Used in 11 patients with RT; all but 1 had tumor growth and all but 4 died	Ricchizzi et al. 2022	https://doi.org/10.3390/cancers14235851	(ricchizzi2022howshouldwe pages 3-5)
Recurrence / malignant transformation	Malignant transformation and metastasis are documented despite “benign” histology in many cases	Malignant transformation in 18 patients; of these, 11 developed metastasis	Ricchizzi et al. 2022	https://doi.org/10.3390/cancers14235851	(ricchizzi2022howshouldwe pages 1-3)
Follow-up duration in pooled MM analysis	Published follow-up is variable and often limited	Median follow-up 18 months; range few days to 35 years	Ricchizzi et al. 2022	https://doi.org/10.3390/cancers14235851	(ricchizzi2022howshouldwe pages 7-8)
Rades therapy cohort	Historical pooled cohort used to compare surgery and RT	89 patients: CTR 46, CTR+RT 3, ITR 23, ITR+RT 17	Rades et al. 2004	https://doi.org/10.1002/cncr.20296	(rades2004therapyofmeningeal pages 2-4, rades2004therapyofmeningeal pages 1-2)
Local control by treatment	Best local control with complete resection; RT improves outcome after incomplete resection	5-year local control: CTR 80%, CTR+RT 100%, ITR+RT 72%, ITR 18%	Rades et al. 2004	https://doi.org/10.1002/cncr.20296	(rades2004therapyofmeningeal pages 2-4, rades2004therapyofmeningeal pages 1-2)
Survival by treatment	Incomplete resection without RT had substantially worse survival	5-year survival: CTR 100%, CTR+RT 100%, ITR+RT 100%, ITR 46%	Rades et al. 2004	https://doi.org/10.1002/cncr.20296	(rades2004therapyofmeningeal pages 2-4, rades2004therapyofmeningeal pages 1-2)
Recurrence by treatment	Recurrence risk sharply higher after incomplete resection alone	Recurrence: CTR 24% (11/46), CTR+RT 0% (0/3), ITR 78% (18/23), ITR+RT 24% (4/17)	Rades et al. 2004	https://doi.org/10.1002/cncr.20296	(rades2004therapyofmeningeal pages 2-4)
RT dose-response signal	Higher conventional RT dose appeared more favorable after incomplete resection	In tumor-confined RT subgroup: 45–55 Gy gave 5-year local control 86% vs 27% with 30–40 Gy	Rades et al. 2004	https://doi.org/10.1002/cncr.20296	(rades2004therapyofmeningeal pages 2-4, rades2004therapyofmeningeal pages 4-5)
Proposed treatment implication	Gross-total resection is preferred; RT is most justified after partial resection, recurrence, or higher proliferative/intermediate-grade lesions	Qualitative recommendation supported by pooled retrospective evidence	Rades et al. 2004; Ricchizzi et al. 2022; Pellerino et al. 2024	https://doi.org/10.1002/cncr.20296; https://doi.org/10.3390/cancers14235851; https://doi.org/10.3390/cancers16142508	(rades2004therapyofmeningeal pages 2-4, ricchizzi2022howshouldwe pages 7-8, pellerino2024primarymeningealmelanocytic pages 1-2)

Table: This table summarizes the main quantitative and distinguishing disease characteristics of meningeal melanocytoma across recent and foundational sources, including epidemiology, clinicopathology, molecular features, and treatment outcomes. It is useful as a compact evidence map for knowledge-base population and citation tracking.

Figures/tables accessed

Treatment algorithms from Ricchizzi et al. (Figures 4–5) were retrieved as cropped images. (ricchizzi2022howshouldwe media a6484091, ricchizzi2022howshouldwe media 138f0f8b)
WHO-aligned pathology flowchart from EURACAN review (Figure 1) was retrieved as cropped images. (pellerino2024primarymeningealmelanocytic media 6f94701f, pellerino2024primarymeningealmelanocytic media 71b6cc54)

Limitations of this report (evidence gaps)

Ontology identifiers (MONDO/MeSH/ICD/Orphanet/OMIM) could not be reliably extracted with the tools used in this run; the report therefore emphasizes peer‑reviewed disease characterization instead. (pellerino2024primarymeningealmelanocytic pages 1-2)
Many therapeutic claims remain retrospective and confounded by heterogeneous reporting; EURACAN and Ricchizzi both highlight the need for registries and prospective studies. (pellerino2024primarymeningealmelanocytic pages 1-2, ricchizzi2022howshouldwe pages 8-10)
Systemic therapy evidence is sparse and largely extrapolated from metastatic melanoma; benefits remain uncertain. (pellerino2024primarymeningealmelanocytic pages 11-12)

References

(pellerino2024primarymeningealmelanocytic pages 2-3): Alessia Pellerino, Robert M. Verdijk, Lucia Nichelli, Nicolaus H. Andratschke, Ahmed Idbaih, and Roland Goldbrunner. Primary meningeal melanocytic tumors of the central nervous system: a review from the ultra-rare brain tumors task force of the european network for rare cancers (euracan). Cancers, 16:2508, Jul 2024. URL: https://doi.org/10.3390/cancers16142508, doi:10.3390/cancers16142508. This article has 19 citations.
(pellerino2024primarymeningealmelanocytic pages 1-2): Alessia Pellerino, Robert M. Verdijk, Lucia Nichelli, Nicolaus H. Andratschke, Ahmed Idbaih, and Roland Goldbrunner. Primary meningeal melanocytic tumors of the central nervous system: a review from the ultra-rare brain tumors task force of the european network for rare cancers (euracan). Cancers, 16:2508, Jul 2024. URL: https://doi.org/10.3390/cancers16142508, doi:10.3390/cancers16142508. This article has 19 citations.
(pellerino2024primarymeningealmelanocytic pages 3-5): Alessia Pellerino, Robert M. Verdijk, Lucia Nichelli, Nicolaus H. Andratschke, Ahmed Idbaih, and Roland Goldbrunner. Primary meningeal melanocytic tumors of the central nervous system: a review from the ultra-rare brain tumors task force of the european network for rare cancers (euracan). Cancers, 16:2508, Jul 2024. URL: https://doi.org/10.3390/cancers16142508, doi:10.3390/cancers16142508. This article has 19 citations.
(pellerino2024primarymeningealmelanocytic pages 6-7): Alessia Pellerino, Robert M. Verdijk, Lucia Nichelli, Nicolaus H. Andratschke, Ahmed Idbaih, and Roland Goldbrunner. Primary meningeal melanocytic tumors of the central nervous system: a review from the ultra-rare brain tumors task force of the european network for rare cancers (euracan). Cancers, 16:2508, Jul 2024. URL: https://doi.org/10.3390/cancers16142508, doi:10.3390/cancers16142508. This article has 19 citations.
(ricchizzi2022howshouldwe pages 1-3): Sarah Ricchizzi, Marco Gallus, Walter Stummer, and Markus Holling. How should we treat meningeal melanocytoma? a retrospective analysis of potential treatment strategies. Cancers, 14:5851, Nov 2022. URL: https://doi.org/10.3390/cancers14235851, doi:10.3390/cancers14235851. This article has 11 citations.
(tsai2023recurrentspinalmeningeal pages 1-3): Mu-Hung Tsai, Wei-Pin Lin, Wei-An Liao, Po-Ying Chiang, and Yu-Ching Lin. Recurrent spinal meningeal melanocytoma at lumbar spine level: a case report. British Journal of Neurosurgery, 37:1163-1166, Jan 2023. URL: https://doi.org/10.1080/02688697.2020.1867062, doi:10.1080/02688697.2020.1867062. This article has 7 citations and is from a peer-reviewed journal.
(ricchizzi2022howshouldwe pages 3-5): Sarah Ricchizzi, Marco Gallus, Walter Stummer, and Markus Holling. How should we treat meningeal melanocytoma? a retrospective analysis of potential treatment strategies. Cancers, 14:5851, Nov 2022. URL: https://doi.org/10.3390/cancers14235851, doi:10.3390/cancers14235851. This article has 11 citations.
(kusters‐vandevelde2015primarymelanocytictumors pages 7-8): Heidi V.N. Küsters‐Vandevelde, Benno Küsters, Adriana C.H. van Engen‐van Grunsven, Patricia J.T.A. Groenen, Pieter Wesseling, and Willeke A.M. Blokx. Primary melanocytic tumors of the central nervous system: a review with focus on molecular aspects. Brain Pathology, 25:209-226, Mar 2015. URL: https://doi.org/10.1111/bpa.12241, doi:10.1111/bpa.12241. This article has 148 citations and is from a domain leading peer-reviewed journal.
(koelsche2015melanotictumorsof pages 1-2): Christian Koelsche, Volker Hovestadt, David T. W. Jones, David Capper, Dominik Sturm, Felix Sahm, Daniel Schrimpf, Sebastian Adeberg, Katja Böhmer, Christian Hagenlocher, Gunhild Mechtersheimer, Patricia Kohlhof, Helmut Mühleisen, Rudi Beschorner, Christian Hartmann, Anne Kristin Braczynski, Michel Mittelbronn, Rolf Buslei, Albert Becker, Alexander Grote, Horst Urbach, Ori Staszewski, Marco Prinz, Ekkehard Hewer, Stefan M. Pfister, Andreas von Deimling, and David E. Reuss. Melanotic tumors of the nervous system are characterized by distinct mutational, chromosomal and epigenomic profiles. Brain Pathology, 25:202-208, Mar 2015. URL: https://doi.org/10.1111/bpa.12228, doi:10.1111/bpa.12228. This article has 87 citations and is from a domain leading peer-reviewed journal.
(koelsche2015melanotictumorsof pages 2-3): Christian Koelsche, Volker Hovestadt, David T. W. Jones, David Capper, Dominik Sturm, Felix Sahm, Daniel Schrimpf, Sebastian Adeberg, Katja Böhmer, Christian Hagenlocher, Gunhild Mechtersheimer, Patricia Kohlhof, Helmut Mühleisen, Rudi Beschorner, Christian Hartmann, Anne Kristin Braczynski, Michel Mittelbronn, Rolf Buslei, Albert Becker, Alexander Grote, Horst Urbach, Ori Staszewski, Marco Prinz, Ekkehard Hewer, Stefan M. Pfister, Andreas von Deimling, and David E. Reuss. Melanotic tumors of the nervous system are characterized by distinct mutational, chromosomal and epigenomic profiles. Brain Pathology, 25:202-208, Mar 2015. URL: https://doi.org/10.1111/bpa.12228, doi:10.1111/bpa.12228. This article has 87 citations and is from a domain leading peer-reviewed journal.
(NCT05984108 chunk 1): Guillaume GAUCHOTTE. Clinical, Radiological, Histologic and Molecular Features of a Cohort of Melanocytic Tumors of the Central Nervous System. Central Hospital, Nancy, France. 2023. ClinicalTrials.gov Identifier: NCT05984108
(kusters‐vandevelde2015primarymelanocytictumors pages 10-11): Heidi V.N. Küsters‐Vandevelde, Benno Küsters, Adriana C.H. van Engen‐van Grunsven, Patricia J.T.A. Groenen, Pieter Wesseling, and Willeke A.M. Blokx. Primary melanocytic tumors of the central nervous system: a review with focus on molecular aspects. Brain Pathology, 25:209-226, Mar 2015. URL: https://doi.org/10.1111/bpa.12241, doi:10.1111/bpa.12241. This article has 148 citations and is from a domain leading peer-reviewed journal.
(ricchizzi2022howshouldwe pages 7-8): Sarah Ricchizzi, Marco Gallus, Walter Stummer, and Markus Holling. How should we treat meningeal melanocytoma? a retrospective analysis of potential treatment strategies. Cancers, 14:5851, Nov 2022. URL: https://doi.org/10.3390/cancers14235851, doi:10.3390/cancers14235851. This article has 11 citations.
(rades2004therapyofmeningeal pages 2-4): Dirk Rades, Steven E. Schild, Marcos Tatagiba, Hugo A. Molina, and Winfried Alberti. Therapy of meningeal melanocytomas. Cancer, 100:2442-2447, Jun 2004. URL: https://doi.org/10.1002/cncr.20296, doi:10.1002/cncr.20296. This article has 106 citations and is from a domain leading peer-reviewed journal.
(pellerino2024primarymeningealmelanocytic pages 7-10): Alessia Pellerino, Robert M. Verdijk, Lucia Nichelli, Nicolaus H. Andratschke, Ahmed Idbaih, and Roland Goldbrunner. Primary meningeal melanocytic tumors of the central nervous system: a review from the ultra-rare brain tumors task force of the european network for rare cancers (euracan). Cancers, 16:2508, Jul 2024. URL: https://doi.org/10.3390/cancers16142508, doi:10.3390/cancers16142508. This article has 19 citations.
(pellerino2024primarymeningealmelanocytic pages 11-12): Alessia Pellerino, Robert M. Verdijk, Lucia Nichelli, Nicolaus H. Andratschke, Ahmed Idbaih, and Roland Goldbrunner. Primary meningeal melanocytic tumors of the central nervous system: a review from the ultra-rare brain tumors task force of the european network for rare cancers (euracan). Cancers, 16:2508, Jul 2024. URL: https://doi.org/10.3390/cancers16142508, doi:10.3390/cancers16142508. This article has 19 citations.
(rades2004therapyofmeningeal pages 1-2): Dirk Rades, Steven E. Schild, Marcos Tatagiba, Hugo A. Molina, and Winfried Alberti. Therapy of meningeal melanocytomas. Cancer, 100:2442-2447, Jun 2004. URL: https://doi.org/10.1002/cncr.20296, doi:10.1002/cncr.20296. This article has 106 citations and is from a domain leading peer-reviewed journal.
(kusters‐vandevelde2015primarymelanocytictumors pages 5-6): Heidi V.N. Küsters‐Vandevelde, Benno Küsters, Adriana C.H. van Engen‐van Grunsven, Patricia J.T.A. Groenen, Pieter Wesseling, and Willeke A.M. Blokx. Primary melanocytic tumors of the central nervous system: a review with focus on molecular aspects. Brain Pathology, 25:209-226, Mar 2015. URL: https://doi.org/10.1111/bpa.12241, doi:10.1111/bpa.12241. This article has 148 citations and is from a domain leading peer-reviewed journal.
(classen2002suprasellarmelanocytomaa pages 6-7): Johannes Classen, Thomas Hehr, Werner Paulus, Karl Plate, and Michael Bamberg. Suprasellar melanocytoma: a case of primary radiotherapy and review of the literature. Journal of Neuro-Oncology, 58:39-46, May 2002. URL: https://doi.org/10.1023/a:1015872207398, doi:10.1023/a:1015872207398. This article has 40 citations and is from a peer-reviewed journal.
(pellerino2024primarymeningealmelanocytic media 6f94701f): Alessia Pellerino, Robert M. Verdijk, Lucia Nichelli, Nicolaus H. Andratschke, Ahmed Idbaih, and Roland Goldbrunner. Primary meningeal melanocytic tumors of the central nervous system: a review from the ultra-rare brain tumors task force of the european network for rare cancers (euracan). Cancers, 16:2508, Jul 2024. URL: https://doi.org/10.3390/cancers16142508, doi:10.3390/cancers16142508. This article has 19 citations.
(rades2004therapyofmeningeal pages 4-5): Dirk Rades, Steven E. Schild, Marcos Tatagiba, Hugo A. Molina, and Winfried Alberti. Therapy of meningeal melanocytomas. Cancer, 100:2442-2447, Jun 2004. URL: https://doi.org/10.1002/cncr.20296, doi:10.1002/cncr.20296. This article has 106 citations and is from a domain leading peer-reviewed journal.
(ricchizzi2022howshouldwe media a6484091): Sarah Ricchizzi, Marco Gallus, Walter Stummer, and Markus Holling. How should we treat meningeal melanocytoma? a retrospective analysis of potential treatment strategies. Cancers, 14:5851, Nov 2022. URL: https://doi.org/10.3390/cancers14235851, doi:10.3390/cancers14235851. This article has 11 citations.
(ricchizzi2022howshouldwe media 138f0f8b): Sarah Ricchizzi, Marco Gallus, Walter Stummer, and Markus Holling. How should we treat meningeal melanocytoma? a retrospective analysis of potential treatment strategies. Cancers, 14:5851, Nov 2022. URL: https://doi.org/10.3390/cancers14235851, doi:10.3390/cancers14235851. This article has 11 citations.
(pellerino2024primarymeningealmelanocytic media 71b6cc54): Alessia Pellerino, Robert M. Verdijk, Lucia Nichelli, Nicolaus H. Andratschke, Ahmed Idbaih, and Roland Goldbrunner. Primary meningeal melanocytic tumors of the central nervous system: a review from the ultra-rare brain tumors task force of the european network for rare cancers (euracan). Cancers, 16:2508, Jul 2024. URL: https://doi.org/10.3390/cancers16142508, doi:10.3390/cancers16142508. This article has 19 citations.
(ricchizzi2022howshouldwe pages 8-10): Sarah Ricchizzi, Marco Gallus, Walter Stummer, and Markus Holling. How should we treat meningeal melanocytoma? a retrospective analysis of potential treatment strategies. Cancers, 14:5851, Nov 2022. URL: https://doi.org/10.3390/cancers14235851, doi:10.3390/cancers14235851. This article has 11 citations.

Ask OpenScientist

OpenScientist Report

Pathophysiology

Histopathology

Pathograph

Phenotypes

Genetic Associations

Treatments

Clinical Trials

Source YAML

References & Deep Research

Deep Research

Disease Characteristics Research Template

Target Disease

Research Objectives

1. Disease Information

2. Etiology

3. Phenotypes

4. Genetic/Molecular Information

5. Environmental Information

6. Mechanism / Pathophysiology

7. Anatomical Structures Affected

8. Temporal Development

9. Inheritance and Population

10. Diagnostics

11. Outcome/Prognosis

12. Treatment

13. Prevention

14. Other Species / Natural Disease

15. Model Organisms

Citation Requirements

Output Format

Comprehensive research report: Meningeal Melanocytoma

Target disease

1. Disease information

1.1 Definition and current classification

1.2 Synonyms and related terms

1.3 Evidence sources and aggregation

2. Etiology

2.1 Causal factors / origin

2.2 Risk factors

2.3 Protective factors and gene–environment interactions

3. Phenotypes (clinical presentation)

3.1 Typical presentations and symptomatology

3.2 Suggested HPO phenotype terms (non-exhaustive)

3.3 Demographics and frequency of presentations

4. Genetic / molecular information

4.1 Key driver alterations (current understanding)

4.2 Mutation frequencies and diagnostic utility (primary literature)

4.3 Epigenomics and methylation profiling

4.4 Pathway-level mechanism (actionable biology)

4.5 Suggested ontology mappings

5. Environmental information

6. Mechanism / pathophysiology

6.1 Causal chain (integrated view)

6.2 Upstream vs downstream

7. Anatomical structures affected

7.1 Primary sites

7.2 Anatomic distribution statistics (pooled data)

8. Temporal development

8.1 Onset and course

8.2 Progression, recurrence, and transformation

9. Inheritance and population

9.1 Epidemiology

9.2 Germline inheritance

10. Diagnostics

10.1 Imaging

10.2 Histopathology and IHC

10.3 Proliferation indices and thresholds

10.4 Differential diagnosis (critical)

10.5 Recommended systemic workup to exclude metastasis

10.6 Molecular diagnostics / methylation

11. Outcome / prognosis

11.1 Surgical extent and radiotherapy influence outcomes

11.2 Recurrence and metastasis

12. Treatment

12.1 Local therapy (real-world standard)

12.2 Systemic therapy (limited evidence; mostly extrapolated)

13. Prevention

14. Other species / natural disease